

CURRICULUM VITAE

WILLIAM DOUGLAS FIGG, SR

Work Address:

National Institutes of Health
National Cancer Institute
Center for Cancer Research
Medical Oncology Branch
Molecular Pharmacology Section
Building 10, Room 5A01, MSC 1910
9000 Rockville Pike
Bethesda, Maryland 20892

Telephone (301) 402-3623
Mobile (240) 338-6898
Fax (301) 402-8606
Email wdfigg@helix.nih.gov

Education:

8/81 - 5/83 Georgetown College, Georgetown, Kentucky,
Major - Biology
8/83 - 11/86 Samford University, School of Pharmacy, Birmingham, AL
Bachelor of Science
9/87 - 8/89 Auburn University, School of Pharmacy, Birmingham, AL
Doctor of Pharmacy
5/01 - 7/03 Columbia University, School of Business, New York, NY and
London Business School, University of London, London, UK,
Master of Business Administration

Post-Graduate Training:

11/86 - 9/87 Internship, University of Alabama Hospital, Birmingham, AL
6/90 - 6/92 Post-Doctoral Fellowship in Clinical Research/Drug Development,
University of North Carolina at Chapel Hill, Chapel Hill, NC

Professional Appointments:

6/83 - 11/86 Pharmacy Externship, Department of Pharmacy,
BMC Princeton Hospital, Birmingham, Alabama (20 hrs/wk)
9/87 - 6/90 Clinical Pharmacist, Department of Pharmacy, University of
Alabama Hospital, Birmingham, Alabama
6/90 - 6/92 Clinical Staff Pharmacist, Department of Pharmacy,
Duke University Medical Center, Durham, North Carolina
(12-20 hrs/wk)
7/92 - 7/95 Clinical Pharmacist, Pharmacy Department, Mary Washington
Hospital, Fredericksburg, Virginia (8 hrs/wk)
7/92 - 8/93 Clinical Investigator, Clinical Pharmacokinetics Section,
Clinical Pharmacology Branch, National Cancer Institute,
Bethesda, Maryland
7/92 - present Senior Staff, Prostate Cancer Clinic, National Cancer Institute,
Bethesda, Maryland

William Douglas Figg

Curriculum Vitae

Page 2 of 57

9/93 - 12/96

Senior Investigator, Section Head, Clinical Pharmacokinetics Section, CPB, DCS, NCI; and Deputy Branch Chief, Clinical Pharmacology Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, Maryland

12/96 - 2/01

Senior Investigator and Head, Clinical Pharmacokinetics Section, Developmental Therapeutics Department, Medicine Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, Maryland

2/01-11/05

Principle Investigator and Head of the Molecular Pharmacology Section, Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute; and Head of the Clinical Pharmacology Scientific Core, Medical Oncology Clinical Research Unit, CCR, NCI; and Head of the Preclinical Pharmacokinetics Core, Molecular Targets Program, CCR, NCI

11/05 - present

Senior Scientist and Head of the Molecular Pharmacology Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute; and Head of the Clinical Pharmacology Program, MOB, CCR, NCI; and Head, Biological Fluid Processing Core, CCR, NCI, National Institutes of Health, Bethesda, Maryland

Professional Licensure:

Alabama State Board of Pharmacy #11217 (15 Sept 1987)
Tennessee State Board of Pharmacy #007039 (21 May 1987)
North Carolina State Board of Pharmacy #11089 (18 Sept 1990)
Virginia State Board of Pharmacy #0202011192 (19 Oct 1993)

Board Certification:

Pharmacotherapy Specialty #291192 (8/91)
recertification 12/99
recertification 12/07

Academic Appointments/Affiliations/Teaching Responsibilities:

Lecturer - Howard University Pharm.D. Program (Oncology Module in Therapeutics course), 1995

Lecturer - Shenandoah University Pharm.D. Program

(Oncology Module in Therapeutics course), (1999-2000)

Graduate Advisor - University of Pittsburgh School of Pharmacy, School of Pharmacy (1996-1999)

Adjunct Professor - University of Maryland School of Pharmacy (1994-present)

Adjunct Clinical Professor - University of Kentucky School of Pharmacy (1993-1999)

Clinical Pharmacology Consultant - Johns Hopkins University (1999-2000)

Adjunct Clinical Associate Professor - University of Michigan School of Pharmacy (2003-present)

Affiliate Professor and Graduate Advisor - Virginia Commonwealth University,

Medical College of Virginia, School of Pharmacy, Department of Pharmaceutics (1997-present)

Lecturer - Columbia University, School of Public Health,

Course - Strategic Management and Healthcare Policy (2004-2007)

Graduate Advisor - Oxford University (2005 - present)

Graduate Advisor - George Washington University, Department of Genetics (2004 - present)

Graduate Advisor - University of Maryland, Molecular and Cell Biology Program (2006 - present)

Graduate Advisor - Johns Hopkins University (2008 - present)

United State Public Health Service Commissioned Corps.:

US Public Health Service Commissioned Officer 0-3 (Lt.), 7/92-12/93
US Public Health Service Commissioned Officer 0-4 (Lt. Commander), 1/94 - 12/98
US Public Health Service Commissioned Officer 0-5 (Commander), 1/99 – 6/06
US Public Health Service Commendation Medal, 1995
US Public Health Service Commissioned Corps Unit Commendation, 2004
US Public Health Service Commissioned Corps Bicentennial Unit Commendation, 1998
US Public Health Service, Pharmacy Professional Advisory Committee (1997 - 2000)
 Subcom. on Pharmaceutical Care (1995 - 1998)
 Chair, Subcommittee on Pharmaceutical Care (1998 - 2000)
 Liason to ACCP (2005 – present)
US Public Health Services Commissioned Corps Medical Review Board (2002)
US Public Health Commissioned Corps Readiness Force
 Basic Response Readiness Certified (2005 – present)
US Public Health Commissioned Corps Assimilation into the Regular Corps, 2007
Deployed to Meridian, Mississippi in Response to Hurricane Katrina –
 Command Staff, Head of Logistics
US Public Health Service Commissioned Corps Citation Medal, 2005
US Public Health Service Commissioned Corps Crisis Response Service Award
 Gulf Coast Hurricanes, 2005
US Public Health Service Commissioned Officer 0-6 (Captain), 7/06 – present
US Public Health Service Commissioned Corps Citation Medal, 2006
US Public Health Service Commissioned Corps Commendation Medal, 2006
US Public Health Service Commissioned Corps OCCO Board (one year appointment)
US Public Health Service Commissioned Corps Functional Group Transformation Team
 (Research Category)
US Public Health Service Commissioned Corps Outstanding Unit Citation, 2007

Professional Affiliations:

American Society of Health-System Pharmacist (1986 – 1992, 2005 - present)
 Abstract Reviewer (1992-2001)
American College of Clinical Pharmacy (1990 - present)
 Research Affairs Committee (1992 - 1994)
 Chairman of Abstract Selection Committee (1997)
 Abstract Reviewer for Oncology Submission (1996 - present)
 Program Committee, 1997 Annual Meeting
 Awards Committee (1997-1999)
 Chair, Subcommittee on the Young Investigator's Award (1998-1999)
 Task Force on Science (1999 - 2001)
 Fellowship Credential Committee (2001 - 2002)
 Research Institute Trustee – Elected member (2003 – 2006)
 Chair, Grants and Fellowship Selection Committee (2006)
American Society for Clinical Pharmacology and Therapeutics (1991 - present)
American College of Clinical Pharmacology (1992 - present)
 Chairman Government Advisory Board (1995 - 1997)
 Program Committee, 1999 Annual Meeting
 Abstract Reviewer (1999)
American Association for Cancer Research (1993 - present)
 EORTC/NCI/AACR program committee (2007)
 Abstract Reviewer EORTC/NCI/AACR meeting (2007)

William Douglas Figg

Curriculum Vitae

Page 4 of 57

Scientific Committee 20th EORTC/NCI/AACR Molecular Targets and
Cancer Therapeutics Symposium
American Society of Clinical Oncology (1993 - present)
Abstract Reviewer (2000)
Program Committee (2000)
American Urological Association (1998 - present)
Association of Military Surgeons of the US (1998 - present)
American Association of Pharmaceutical Science (2005 – present)
American Pharmacists Association (2005 – present)
Hematology/Oncology Pharmacy Association (2005 – present)

Professional Activities/Committees (intramural and extramural):

National Institutes of Health, Pharmacy and Therapeutics Committee,
NCI Representative (1994 - present)
Board of Pharmacotherapy Specialty, Item Writer for Exam (1991 - 1994)
National Association of Boards of Pharmacy Licensure Examination, Item Writer (1996)
Howard Hughes Medical Institute Scholars Program, Selection Committee (1996, 1998)
Advisory Comm. for Endocrinology Section, National Institute of Child Health and
Human Development (1997)
Head, Clinical Pharmacology Special Interest Group, National Institutes of Health (1997 - 1998)
Head, Clinical Pharmacology Special Interest Subgroup in Oncology (1998 - 2002)
NCI's Prostate Cancer Task Force (1997 - 1998)
NCI's Prostate Cancer Progress Review Group (1997 - 1998)
2003 Committee to Evaluate the progress of the 1998 Prostate PRG
Co-Chair, NCI's Tumor Angiogenesis and Invasion Think Tank (1998 - 2002)
NCI's Ad Hoc Tenure and Promotion Committee Reviewer (1999)
American Association of Pharmaceutical Scientists - Visiting Scientist –
MCV School of Pharmacy (2000)
US Pharmacopeia, Scientific Advisory Board for Oncology (2000 - 2003)
NCI, CCR's Early Drug Development Committee (2004 – 2005)
NCI, CCR's Tissue Repository Committee (2004-2005)
NCI's Protocol Monitoring and Review Committee, Ad Hoc Clinical Pharmacology Reviewer
(2000 - 2002)
NCI's Medical Oncology Branch Protocol Review Committee (1999 - 2001)
NCI's Cancer Therapeutics Branch Protocol Review Committee (2001 - 2005)
NCI's Medical Oncology Branch Protocol Review Committee (2006 – present)
NCI's Vascular Biology Faculty – Steering Committee (2001 - present)
Co-Chair, NCI's Vascular Biology Faculty (2001 - 2004)
Chair, NCI's Vascular Biology Faculty (2005 – 2006)
NCI's GU Malignancy Faculty – Steering Committee (2001 - present)
NCI's Molecular Target Faculty – Steering Committee (2002 - present)
NCI's Institutional Review Board (2002 - 2004)
NCI's Technology Review Group (2005 – present)
NCI's Joint Drug Development Committee, voting member (2005 – present)
NCI's Pharmacodynamic Endpoint Meeting – Chaired (2006)
NCI's Molecular Target Prioritization Meeting – Chaired (2006)
NCI's Drug Development Prioritization Meeting – Chaired (2006)
NCI's Medical Oncology Chief Search Committee (2006)
NIH's Scientific Directors Ad Hoc Committee on Biological Samples (2006-2007)
NIH's Clinical Pharmacology Program and Course – Steering Committee (2006 – present)
NCI's Friday Medical Oncology Lecture Series (co-coordinator) (2005 - present)
NCI's Prostate Cancer Teaching Conference (coordinator) (1987 – present)

William Douglas Figg**Curriculum Vitae**

Page 5 of 57

NCI's Molecular Target Development Program (review committee) 2007
2008 7th Annual NIH Oxford/Cambridge Colloquium – Program/Organizing Chair
NCI's Molecular Targets Development Program – Chair of the Steering Committee

Editorial Appointments/Activities:

Assistant Editor	1991-present	DrugDex Information Systems (MicroMedex)
Editorial Board	1997-present	Pharmacotherapy
External Advisory Board	1994-2001	Physician Data Query, Clinical Trial Database
Editorial Board	1994-1997	Oncology Report
Editorial Board	1995-present	Journal of Clinical Pharmacology
Editorial Board	1997-2001	The Prostate Journal
Associate Editor	1999-present	Clinical Cancer Research
Editorial Board	2000-present	The Journal for Drug Evaluation
Editorial Board	2000	Pediatric Drug Therapy
Section Editor	2000-2005	Clinical Prostate Cancer
Editorial Board	2001-present	Cancer Biology and Therapy
Editorial Board	2002-present	International Journal of Cancer
Editorial Board	2002-present	Molecular Cancer Therapeutics
Editorial Board	2004-present	Current Cancer Therapy Reviews
Editorial Board	2005-present	Journal American Pharmacists Association
Editorial Board	2005-present	Recent Patents on Anti-Cancer Drug Discovery
Editorial Board	2006-present	Clinical Genitourinary Cancer
Editorial Board	2007-present	The Open Cancer Letters
Reviewer:	Journal of Chromatograph B	Pharmacogenetics
	Investigational New Drugs	Antimicrobial Agents and Chemotherapy
	Southern Medical Journal	American Journal Pathology
	Biochemical Pharmacology	Cancer Research
	Annals of Pharmacotherapy	Journal of Oncology Pharmacy Practice
	Cancer Investigation	Journal American Medical Association
	British Journal of Cancer	J of Pharmacokinetic and Pharmacodynamics
	Cancer	Journal of National Cancer Institute
	Analytica Chimica Acta	Journal Clinical Investigation
	Lipids	American Hospital Formulary Service
	Biotechniques	Molecular Medicine Today
	Blood	Trends in Pharmacology Science
	Molecular Pharmacology	Human Genetics
	Clin Pharmacology Therapeutics	Cancer Chemotherapy Pharmacology
	FASEB Letters	Nature Cancer Review
	Journal of Urology	The Oncologist
	Journal of Molecular Medicine	Urology
	J Pharmacology Exp Therapeutics	Laboratory Investigation
	The Pharmacogenomic Journal	Cancer Epidemiology, Biomarkers and Prevention
	Biol of Blood Marrow Transpl	Journal of Clinical Oncology
	European Journal of Cancer	Journal of Pharmacy and Pharmacology
	Neoplasia	In Vitro Cellular and Developmental Biology
	Journal of Pathology	British Journal Hematology
	Proc Natl Academy Science	European Urology
	Oncogene	Leukemia
	Human Mutation	Life Sciences
	Lancet	Biorganic & Medicinal Chemistry

University Organizations/Activities:

Golf Team - Georgetown College, 1982
Kappa Alpha - Georgetown College, 1982
Phi Delta Chi - Samford University, 1984

Awards, Honors and Fellowships:

Beta Beta Beta, Samford University, 1985
Outstanding Young Men of America, 1987
Glaxo Research Institute Fellowship, 1990-92
Recipient NIH Research Award - Student Loan Repayment, 1992-93
Who's Who in the East, 1998, 1999, 2000
Who's Who in America, 2000
1996 McKeen Cattell Award from American College of Clinical Pharmacology's
Journal of Clinical Pharmacology (co-author)
1997 Fellow, American College of Clinical Pharmacy
2000 Fellow, American College of Clinical Pharmacology
2001 Allen J. Brands Clinical Pharmacist of the Year Award,
US Public Health Service Commissioned Officers Association
2003 Association of Military Surgeons of the United States,
Clinical Pharmacist of the Year Award
2003 Center for Cancer Research Federal Technology Transfer Award
2004 Ohio County High School, Hartford, KY – Alumni Professional Achievement Award
2003 US Navy, Meritorious Unit Commendation
2004 Academy of Medicine, Washington, DC – elected member
2004 Center for Cancer Research Federal Technology Transfer Award
2005 Leon I. Goldberg Young Investigator Award,
American Society of Clinical Pharmacology and Therapeutics
2005 19th Annual Singapore World Pharmacy Congress, Keynote Lecture and Award
2005 Center for Cancer Research Federal Technology Transfer Award
2006 Center for Cancer Research Federal Technology Transfer Award
2007 Center for Cancer Research Federal Technology Transfer Award
2007 The Annual Graduate Student Invited Lecture, Dartmouth College of Medicine, Department of
Pharmacology and Toxicology
2007 NVCA Teacher of the Year Award
2007 NIH Clinical Center Director's Award
2008 Columbia University Business School Non-Profit Alumni Award
2008 Samford University School of Pharmacy – Commencement Address
2008 Russell R. Miller Award, American College of Clinical Pharmacy

Executive Management Training:

Johns Hopkins University, School of Business, Baltimore, MD,
Leadership and Organizational Behavior, 1994

Wharton School of Management, University of Pennsylvania, Philadelphia, PA,
Essentials of Management, 1998, 1999

Certifications:

Basic Life Support (1989 – present)

Bibliography:

- 1 Avent CK, Krinsky D, Kirklin JK, Bourge RC, **Figg WD**. Synergistic Nephrotoxicity Due to Ciprofloxacin and Cyclosporine. *Am J Med* 1988;85:452-3.
- 2 **Figg WD**. Cyclosporine-Induced Hyperuricemia and Gout. *N Engl J Med* (letter) 1990;322:334-5.
- 3 Thompson G, **Figg WD**. Diarrhea Precipitated by Oral Liquid Medication. *Am J Med* (letter) 1990;89:697.
- 4 Bourge RC, Kirklin JK, Naftel DC, **Figg WD**, Williams-White C, Ketchum C. Diltiazem-Cyclosporine Interaction in Cardiac Transplant Patients: Impact on Cyclosporine Dose and Medication Costs. *Am J Med* 1991;90:402-4.
- 5 **Figg WD**. Peripheral Neuropathy in HIV Patient after Isoniazid Therapy Initiated. *Annals of Pharmacotherapy* (letter) 1991;25:100-1.
- 6 **Figg WD**. Aseptic Meningitis Associated with Muromonab-CD3. *Annals of Pharmacotherapy* (letter) 1991;25:1395.
- 7 **Figg WD**. Ondansetron versus Dexamethasone. *Lancet* (letter) 1991;338:946.
- 8 Thibault A, **Figg WD**, Cooper MR, Prindiville SA, Sartor AO, Headlee DJ, Myers CE. Anaphylactoid Reaction with Suramin. *Pharmacotherapy* 1993;13:656-7.
- 9 Erratum: Anaphylactoid Reaction with Suram. *Pharmacotherapy* 1994;14:125.
- 10 **Figg WD**, Thibault A. Book Review: Oxford Textbook of Clinical Pharmacology and Drug Therapy. *Annals of Pharmacotherapy* 1993;27:797.
- 11 **Figg WD**, Graham CL, Hak LJ, Dukes GE. Ondansetron: A Novel Antiemetic Agent. *S Med J* 1993;86:497-502.
- 12 Thibault A, **Figg WD**. Book Review: Cancer of the Prostate. *J Natl Cancer Inst* 1993;85:1958-9.
- 13 Sartor O, Cooper M, Weinberger M, Headlee D, Thibault A, Tompkins A, Steinberg S, **Figg WD**, Linehan WM, Myers CE. Surprising Activity of Flutamide Withdrawal, When Combined with Aminoglutethimide, in Treatment of "Hormone-Refractory" Prostate Cancer. *J Natl Cancer Inst* 1994;86:222-7.
- 14 **Figg WD**, Yeh HJC, Thibault A, Pluda JM, Itoh F, Yarchoan R, Cooper MR. Assay of the Antiangiogenic Compound, TNP-470, and One of its Metabolites, AGM-1883, by Reversed-Phase High Performance Liquid Chromatography in Plasma. *J Chrom B* 1994;652:187-94.
- 15 Thibault A, Cooper MR, **Figg WD**, Venzon DJ, Sartor AO, Tompkins AC, Weinberger MS, Headlee DJ, McCall NA, Samid D, Myers CE. A Phase I and Pharmacokinetic Study of Intravenous Phenylacetate in Patients with Cancer. *Cancer Res* 1994;54:1690-4.

- 16 Thibault A, **Figg WD**, McCall NA, Samid D, Myers CE, Cooper MR. A Simultaneous Assay of the Differentiating Agents, Phenylacetic Acid and Phenylbutyric Acid, and One of Their Metabolites, Phenylacetylglutamine, by Reversed-Phase, High Performance Liquid Chromatography. *J Liq Chrom* 1994;17:2895-900.
- 17 **Figg WD**, Thibault A, Sartor AO, Mays D, Headlee D, Calis KA, Cooper MR. Hypothyroidism Associated with Aminoglutethimide in Patients with Prostate Cancer. *Arch Int Med* 1994;154:1023-5.
- 18 **Figg WD**, Walls RG, Cooper MR, Thibault A, Sartor O, McCall NA, Myers CE, Samid D. *In Vitro* Antitumor Effect of Hydroxyurea on Hormone-Refractory Prostate Cancer Cells and its Potentiation by Phenylbutyrate. *Anti-Cancer Drugs* 1994;5:336-42.
- 19 **Figg WD**, Cooper MR, Thibault A, Headlee D, Humphrey J, Bergan RC, Reed E, Sartor O. Acute Renal Toxicity Associated with Suramin in the Treatment of Prostate Cancer. *Cancer* 1994;74:1612-4.
- 20 Foss FM, Borkowski TA, Gilliom M, Stetler-Stevenson MA, Jaffe ES, **Figg WD**, Tompkins A, Bastian A, Nylén P, Woodworth T, Udey MC, Sausville EA. Chimeric Fusion Protein Toxin DAB486IL-2 in Advanced Mycosis Fungoides and the Sezary Syndrome: Correlation of Activity and Interleukin-2 Receptor Expression in a Phase II Study. *Blood* 1994;84:1765-74.
- 21 **Figg WD**, Stevens JA, Cooper MR. Adaptive Control With Feedback of Suramin Using Intermittent Infusions. *J Clin Oncol* (letter) 1994;12:1523-4.
- 22 **Figg WD**. Angiogenesis: A Therapeutic Target for Tumor Suppression. *Issues in Pharmacotherapy* 1994;14:3.
- 23 **Figg WD**, Sartor O, Cooper MR, Thibault A, Bergan RC, Dawson N, Reed E, Myers CE. Prostate Specific Antigen Decline Following the Discontinuation of Flutamide in Patients with Stage D2 Prostate Cancer. *Am J Med* 1995;98:412-4.
- 24 **Figg WD**, Dukes GE, Lesesne HR, Carson SW, Songer SS, Pritchard JF, Hermann DJ, Powell JR, Hak LJ. Comparison of Quantitative Methods to Assess Hepatic Function: Pugh's Classification, Indocyanine Green, Antipyrine, and Dextromethorphan. *Pharmacotherapy* 1995;15:693-700.
- 25 Thibault A, Samid D, Cooper MR, **Figg WD**, Tompkins AC, Patronas N, Headlee DJ, Kohler DR, Venzon DJ, Myers CE. Phase I Study of Phenylacetate Administered Twice Daily to Patients with Cancer. *Cancer* 1995;75:2932-8.
- 26 Piscitelli SC, Thibault A, **Figg WD**, Tompkins A, Headlee D, Lieberman R, Samid D, Myers CE. Disposition of Phenylbutyrate and its Metabolites, Phenylacetate and Phenylacetylglutamine. *J Clinical Pharmacology* 1995;35:368-73.
- 27 **Figg WD**, McCall NA, Reed E, Sartor O. The *in vitro* Response of Four Antisteroid Receptor Agents on the Hormone-Responsive Prostate Cancer Cell Line LNCaP. *Oncol Report* 1995;2:295-8.
- 28 Bitton RJ, **Figg WD**, Venzon DJ, Dalakas MC, Bowden C, Headlee D, Reed E, Myers CE, Cooper MR. Pharmacologic Variables Associated with the Development of Neurologic Toxicity in Patients Treated with Suramin. *J Clin Oncol* 1995;13:2223-9.
- 29 **Figg WD**, Middleman MN, Sartor O. Mutated Androgen Receptors of Prostate-Cancer Cells. *N Engl J Med* (letter) 1995;333:1010.

- 30 **Figg WD**, Thibault A, Cooper MR, Reid B, Headlee D, Dawson N, Kohler DR, Reed E, Sartor O. A Phase I Study of the Somatostatin Analogue Somatuline in Patients with Metastatic Hormone-Refractory Prostate Cancer. *Cancer* 1995;75:2159-64.
- 31 McCall NA, Samid D, **Figg WD**. Stability of Sodium Phenylacetate and Sodium Phenylbutyrate in Parenteral Large-Volume Sterile Water. *Drug Stability* 1995;1:54-8.
- 32 Danesi R, **Figg WD**, Reed E, Myers CE. Paclitaxel (Taxol[®]) Inhibits Protein Isoprenylation and Induces Apoptosis in PC-3 Human Prostate Cancer Cells. *Mol Pharmacol* 1995;47:1106-11.
- 33 Sausville EA, Headlee D, Stetler-Stevenson M, Jaffe ES, Solomon D, **Figg WD**, Herdt J, Kopp WC, Rager H, Steinberg SM, Ghetie V, Schindler J, Uhr J, Wittes RE, Vitetta ES. Continuous Infusion of the Anti-CD22 Immunotoxin IgG-RFB4-SMPT-dgA in Patients with B-Cell Lymphoma: A Phase I Study. *Blood* 1995;85:3457-65.
- 34 **Figg WD**, Cole KA, Reed E, Steinberg SM, Piscitelli SC, Davis PA, Soltis MJ, Jacob J, Boudoulas S, Goldspiel B, Sarosy G, Liotta LA, Kohn EC. Pharmacokinetics of Orally Administered Carboxyamido-triazole, an Inhibitor of Calcium-mediated Signal Transduction. *Clin Cancer Res* 1995;1:797-803.
- 35 Dawson NA, Cooper MR, **Figg WD**, Headlee DJ, Thibault A, Bergan RC, Steinberg SM, Sausville EA, Myers CE, Sartor O. Antitumor Activity of Suramin in Hormone-Refractory Prostate Cancer Controlling for Hydrocortisone Treatment and Flutamide Withdrawal as Potentially Confounding Variables. *Cancer* 1995;76:453-62.
- 36 Middleman MN, Lush RM, Sartor O, Reed E, **Figg WD**. Prolonged Response to Flutamide Withdrawal and Initiation of Aminoglutethimide in a Patient with Metastatic Prostate Cancer. *J Oncol Pharm Practice* 1995;1:45-7.
- 37 Guetta V, Lush RM, **Figg WD**, Waclawiw MA, Cannon RO. Effects of the Antiestrogen Tamoxifen on Low-Density Lipoprotein Concentrations and Oxidation in Postmenopausal Women. *Am J Cardiology* 1995;76:1072-3.
- 38 Bitton RJ, **Figg WD**, Reed E. A Preliminary Risk-Benefit Assessment of Paclitaxel. *Drug Safety* 1995;12:196-208.
- 39 Bowden CJ, **Figg WD**, Dawson NA, Sartor O, Bitton RJ, Weinberger MS, Headlee D, Reed E, Myers CE, Cooper MR. A Phase I/II Study of Continuous Infusion Suramin in Patients with Hormone-Refractory Prostate Cancer: Toxicity and Response. *Cancer Chemother Pharmacology* 1996;39:1-8.
- 40 Sartor O, **Figg WD**. Mifepristone: Antineoplastic Studies. In Pitkin RM, Scott JR (Editors) Clinical Obstetrics and Gynecology. Published by Lippincott-Raven, Philadelphia, PA, 1996:498-505.
- 41 **Figg WD**, Middleman MN, Sartor O. Therapeutic Options in Patients with Hormone-Refractory Prostate Cancer. *American J Med* (letter) 1996;100:243-4.
- 42 Tisdale JF, **Figg WD**, Reed E, McCall NA, Alkins BR, Horne MK. Severe Thrombocytopenia in Patients Treated with Suramin: Evidence for an Immune Mechanism in One. *Am J Hematol* 1996;51:152-7.
- 43 **Figg WD**, Ammerman K, Patronas N, Steinberg SM, Walls RG, Dawson N, Reed E, Sartor O. Lack of Correlation Between Prostate Specific Antigen and the Presence of Measurable Soft Tissue Metastases in Hormone-Refractory Prostate Cancer. *Cancer Invest* 1996;14:513-7.

- 44 Lush RM, Nguyen BY, Cundy KC, Bauza S, Sogocio T, Stevens J, Piscitelli S, Venzon D, Yarchoan R, **Figg WD**. Pharmacokinetics of (s)-9-(2-Phosphonylmethoxyethyl)adenine (PMEA) and when Administered in Combination with Zidovudine (AZT). *J Applied Ther* 1996;1:13-8.
- 45 Walls R, Thibault A, Lui L, Wood C, Kozlowski JM, **Figg WD**, Sampson ML, Elin RJ, Samid D. The Differentiating Agent Phenylacetate Increases Prostate-Specific Antigen Production by Prostate Cancer Cells. *The Prostate* 1996;29:177-82.
- 46 Walther MM, **Figg WD**, Linehan WM. Intravesical Suramin: A Novel Agent for the Treatment of Superficial Transitional-Cell Carcinoma of the Bladder. *World J Urol* 1996;14:S8-S11.
- 47 Middleman MN, Lush RM, **Figg WD**. The Mutated Androgen Receptor and Its Implications for the Treatment of Metastatic Carcinoma of the Prostate. *Pharmacotherapy* 1996;16:376-81.
- 48 Lush RM, **Figg WD**, Pluda JM, Bitton R, Headlee D, Kohler D, Reed E, Sartor O, Cooper MR. A Phase I Study of Pentosan Polysulfate Sodium in Patients with Advanced Malignancies. *Annals of Oncology* 1996;7:939-44.
- 49 Middleman MN, Lush RM, Sartor O, Reed E, **Figg WD**. Treatment Approaches for Metastatic Cancer of the Prostate based on Recent Molecular Evidence. *Cancer Treatment Rev* 1996;22:105-18.
- 50 Kohn EC, Reed E, Sarosy G, Christian M, Link CJ, Cole K, **Figg WD**, Davis PA, Jacob J, Goldspiel B, Liotta L. Clinical Investigation of a Cytostatic Calcium Influx Inhibitor in Patients with Refractory Cancer. *Cancer Res* 1996;56:569-73.
- 51 Thibault A, Samid D, Tompkins AC, **Figg WD**, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, Reed E, Myers CE. Phase I Study of Lovastatin, an Inhibitor of the Mevalonate Pathway, in Patients with Cancer. *Clin Cancer Res* 1996;2:483-91.
- 52 **Figg WD**, Dukes GE, Pritchard JF, Hermann DJ, Lesesne HR, Carson SW, Songer SS, Powell JR, Hak LJ. Pharmacokinetics of Ondansetron in Patients with Hepatic Insufficiency. *J Clinical Pharmacology* 1996;36:206-15.
- 53 **Figg WD**, Dawson N, Middleman MN, Brawley O, Lush RM, Senderowicz A, Steinberg SM, Tompkins A, Reed E, Sartor O. Flutamide Withdrawal and Concomitant Initiation of Aminoglutethimide in Patients with Hormone Refractory Prostate Cancer. *Acta Oncol* 1996;35:763-5.
- 54 Boudoulas S, Lush RM, McCall NA, Samid D, Reed E, **Figg WD**. Plasma Protein Binding of Phenylacetate and Phenylbutyrate, Two Novel Antineoplastic Agents. *Ther Drug Monit* 1996;18:714-20.
- 55 Dawson NA, Lush RM, Steinberg SM, Tompkins AC, Headlee DJ, **Figg WD**. Suramin-Induced Neutropenia. *Eur J Cancer* 1996;32A:1534-9.
- 56 Stone MJ, Sausville EA, Fay JW, Headlee D, Collins RH, **Figg WD**, Stetler-Stevenson M, Jain V, Jaffe ES, Solomon D, Lush RM, Senderowicz A, Ghetie V, Schindler J, Uhr JW, Vitetta ES. A Phase I Study of Bolus vs. Continuous Infusion of the Anti-CD19 Immunotoxin, IgG-HD37-dgA in Patients with B Cell Lymphoma. *Blood* 1996;88:1188-97.
- 57 Simmons BR, Bauer KS, McCall NA, Kohn EC, **Figg WD**. An optimized Method for the Quantitation of Carboxyamido-triazole (CAI) in Human Plasma with Solid Phase Extraction and Reverse Phase HPLC. *Analyt Let* 1996;30:2009-21.

- 58 Lush RM, **Figg WD**. Book Review: Principles of Antineoplastic Drug Development and Pharmacology. *Annals Pharmacotherapy* 1997;31:377.
- 59 Dixon SC, Soriano BJ, Lush RM, Borner MM, **Figg WD**. Apoptosis: Its Role in the Development of Malignancies and Its Potential as a Novel Therapeutic Target. *Annals Pharmacotherapy* 1997;31:76-82.
- 60 Piscitelli SC, Reiss WG, **Figg WD**, Petros WP. Pharmacokinetic Studies with Recombinant Cytokines: Scientific Issues and Practical Considerations. *Clinical Pharmacokinetic* 1997;32:368-81.
- 61 **Figg WD**, Feuer J, Bauer KS. Management of Hormone-Sensitive Metastatic Prostate Cancer. *Cancer Practice* 1997;5:258-263.
- 62 Masiero L, **Figg WD**, Kohn EC. New Anti-angiogenesis Agents: Review of Experience with Carboxyamino-triazole (CAI), Thalidomide, TNP-470, and interleukin-12. *The Angiogenesis J* 1997;1:23-35.
- 63 **Figg WD**, Pluda JM, Lush RM, Saville MW, Wyvill K, Reed E, Yarchoan R. The Pharmacokinetics of TNP-470, A New Angiogenesis Inhibitor. *Pharmacotherapy* 1997;17:91-7.
- 64 Lush RM, Meadows B, Fojo AT, Kalafsky G, Smith HT, Bates S, **Figg WD**. Initial Pharmacokinetics and Bioavailability of PSC 833, a P-Glycoprotein Antagonist. *J Clinical Pharmacology* 1997;37:123-8.
- 65 **Figg WD**, Christian MC, Lush R, Link CJ, Davis P, Kohn E, Sarosy G, Rothenberg ML, Weiss RB, Ryan N, Jacobs J, Reed E. Pharmacokinetics of Elemental Platinum (Ultrafiltrate and Total) After a Thirty Minute Intravenous Infusion of Ormaplatin. *Biopharm Drug Disp* 1997;18:347-359.
- 66 Piscitelli SC, Forrest A, Lush RM, Ryan N, Whitfield LR, **Figg WD**. Pharmacometric Analysis of the Effect of Furosemide on Suramin Pharmacokinetics. *Pharmacotherapy* 1997;17:431-7.
- 67 Walsh TJ, Whitcomb T, Piscitelli S, **Figg WD**, Hill S, Chanock SJ, Jarosinski P, Gupta R, Pizzo PA. Safety, Tolerance, and Pharmacokinetics of Amphotericin B Lipid Complex in Children with Hepatosplenic Candidiasis. *Antimicrob Agents Chemother* 1997;41:1944-8.
- 68 Senderowicz AM, Vitetta E, Headlee D, Ghetie V, Uhr JW, **Figg WD**, Lush RM, Stetler-Stevenson M, Kershaw G, Kingma DW, Jaffe E, Sausville EA. Complete Sustained Response of a Refractory Post-Transplantation, Large B-cell Lymphoma to an Anti-CD22 Immunotoxin. *Annals Internal Med* 1997;126:882-5.
- 69 Bartlett DL, Buell JF, Libutti SK, Reed E, Lee KB, **Figg WD**, Venzon DJ, Alexander HR. A Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion with Tumor Necrosis Factor and Cisplatin in the Treatment of Peritoneal Carcinomatosis. *Cancer* 1998;83:1251-61. Ma GY, Bartlett DL, Reed E, **Figg WD**, Lush RM, Lee KB, Libutti SK, Alexander HR. Continuous Hyperthermic Peritoneal Perfusion with Cisplatin for the Treatment of Peritoneal Mesothelioma. *Cancer J Sci Am* 1997;3:174-9.
- 70 Ma GY, Bartlett DL, Reed E, **Figg WD**, Lush RM, Lee KB, Libutti SK, Alexander HR. Continuous Hyperthermic Peritoneal Perfusion with Cisplatin for the Treatment of Peritoneal Mesothelioma. *Cancer J Sci Am* 1997;3:174-9.
- 71 Simmons BR, Lush RM, **Figg WD**. A Reversed-Phase high performance liquid chromatography method using Solid Phase Extraction to Quantitate Thalidomide in Human Serum. *Analy Chim Acta* 1997;339:91-7.

- 72 Bergan RC, Walls R, **Figg WD**, Dawson NA, Headlee D, Tompkins A, Steinberg SM, Reed E. Similar Clinical Outcomes in African American and non-African American Males Treated with Suramin for Metastatic Prostate Cancer. *J Natl Med Assoc* 1997;89:622-8.
- 73 Dawson NA, **Figg WD**, Cooper MR, Sartor O, Bergan RC, Senderowicz A, Steinberg SM, Tompkins A, Weinberger BM, Sausville EA, Reed E, Myers CE. A Phase II Trial of Suramin, Leuprolide, and Flutamide in Previously Untreated Metastatic Prostate Cancer. *J Clin Oncol* 1997;15:1470-7.
- 74 **Figg WD**, Kroog G, Duray P, Walther MM, Patronas N, Sartor O, Reed E. Flutamide Withdrawal Plus Hydrocortisone Resulted in Clinical Complete Response in a Patient with Prostate Carcinoma. *Cancer* 1997;79:1964-8.
- 75 Dixon S, Zalles A, Giordano C, Venzon D, Lush RM, Reed E, **Figg WD**. In vitro Effect of Gallium Nitrate when combined with Ketoconazole in the Prostate Cancer Cell Line PC-3. *Cancer Letter* 1997;113:111-6.
- 76 Kohn EC, **Figg WD**, Sarosy GA, Bauer KS, Davis PA, Soltis MJ, Tompkins A, Liotta LA, Reed E. Phase I Trial of Micronized Formulation Carboxyamidotriazole in Patients with Refractory Solid Tumors: Pharmacokinetics, Clinical Outcome and Comparison of Formulations. *J Clinical Oncology* 1997;15:1985-93.
- 77 Piscitelli SC, **Figg WD**, Hahn B, Kelly G, Thomas S, Walker RE. Single-Dose Pharmacokinetics of Thalidomide in Human Immunodeficiency Virus-Infected Patients. *Antimicrob Agents Chemother* 1997;41:2797-9.
- 78 Dawson N, **Figg WD**, Brawley O, Bergan RC, Cooper MR, Senderowicz AM, Headlee D, Steinberg SM, Sutherland M, Patronas N, Sausville E, Linehan M, Reed E, Sartor O. A Phase II Study of Suramin Plus Aminoglutethimide in Two Cohorts of Patients with Androgen-Independent Prostate Cancer: Simultaneous Antiandrogen Withdrawal and Prior Antiandrogen Withdrawal. *Clin Cancer Res* 1998;4:37-44.
- 79 Welles L, Saville MW, Lietzau J, Pluda JM, Wyvill KM, Feuerstein I, **Figg WD**, Lush R, Odom J, Wilson WH, Fajardo MT, Humphrey RW, Feigal E, Tuck D, Steinberg SM, Broder S, Yarchoan R. Phase II Trial with Dose Titration of Paclitaxel for the Therapy of Human Immunodeficiency Virus-Associated Kaposi's Sarcoma. *J Clinical Oncology* 1998;16:1112-21.
- 80 Thibault A, **Figg WD**, Bergan RC, Lush RM, Myers CE, Tompkins A, Reed E, Samid D. A Phase II Study of 5-Aza-2'-Deoxycytidine (Decitabine) in Hormone Independent Metastatic (D2) Prostate Cancer. *Tumori* 1998;84:87-9.
- 81 Sartor O, Weinberger M, Moore A, Li A, **Figg WD**. Effect of Prednisone on Prostate-Specific Antigen in Patients with Hormone Refractory Progressive Prostate Cancer. *Urology* 1998;52:252-6.
- 82 Feuer JA, Lush RM, Venzon D, Duray P, Tompkins A, Sartor O, **Figg WD**. Elevated Carcinomembryonic Antigen in Patients with androgen-independent Prostate Cancer. *J Invest Med* 1998;46:66-72.
- 83 Bauer KS, Dixon SC, **Figg WD**. Inhibition of Angiogenesis by Thalidomide Requires Metabolic Activation which is Species-Dependent. *Biochem Pharmacology* 1998;55:1827-34.
- 84 Horti J, **Figg WD**, Weinberger B, Kohler D, Sartor O. A Phase II Study of Bromocriptine in Patients with Androgen Independent Prostate Cancer. *Oncology Report* 1998;5:893-6.

William Douglas Figg

Curriculum Vitae

Page 13 of 57

- 85 Dixon SC, Horti J, Guo Y, Reed E, **Figg WD**. Methods for Extracting and Amplifying Genomic DNA isolated from Frozen Serum. *Nature Biotechnol* 1998;16:91-4.
- 86 Alexander HR, Brown CK, Bartlett DL, Libutti SK, **Figg WD**, Raje S, Turner E. Augmented Capillary Leak During Isolated Hepatic Perfusion (IHP) Occurs Via Tumor Necrosis Factor Independent Mechanisms. *Clin Cancer Res* 1998;4:2357-62.
- 87 Sausville EA, Lush RM, Headlee D, Smith AC, **Figg WD**, Arbuck SG, Senderowicz AM, Fuse E, Tanii H, Kuwabara T, Kobayashi S. Clinical Pharmacology of UCN-01: Initial Observations and Comparison to Preclinical Models. *Cancer Chemother Pharmacol* 1998;42(Suppl)S54-9.
- 88 Piscitelli SC, Vogel S, **Figg WD**, Raje S, Forrest A, Metcalf JA, Baseler M, Falloon J. Alteration in Indinavir Clearance During Interleukin-2 Infusions in Patients Infected with the Human Immunodeficiency Virus. *Pharmacotherapy* 1998;18:1212-6.
- 89 **Figg WD**, Kim G. The Role of Angiogenesis Inhibition in Metastatic Prostate Cancer. *Adv Prostate Cancer* 1998;8:2-5.
- 90 Fuse E, Tannii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, Sasaki Y, Tanigawara Y, Lush RM, Headlee D, **Figg WD**, Arbuck SG, Senderowicz AM, Sausville EA, Akinaga S, Kuwabara T, Kobayashi S. Unpredicted Clinical Pharmacology of UCN-01 Caused by Specific Binding to Human alpha1-acid glycoprotein. *Cancer Res* 1998;58:3248-53.
- 91 Bauer KC, Lush RM, Rudek MA, **Figg WD**. Novel Targets in Cancer Therapy: Angiogenesis, Matrix Metalloproteinase, Cyclin-Dependent Kinases, and Signal Transduction. *Highlights in Oncology Pract* 1998;16:3-11.
- 92 Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L, Steinberg S, **Figg WD**, Tompkins A, Arbuck S, Sausville EA. A Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-dependent Kinase Inhibitor, in Patients with Refractory Neoplasms. *J Clin Oncol* 1998;16:2986-99.
- 93 Bauer KS, Kohn EC, Lush RM, Steinberg SM, Davis P, Kohler D, Reed E, **Figg WD**. Pharmacokinetics and Relative Bioavailability of Carboxyamido-triazole with Respect to Food and Time of Administration: Use of a Single Model for Simultaneous Determination of Changing Parameters. *J Pharmacokin Biopharm* 1998;26:673-87.
- 94 Arah IN, Dixon SC, Horti J, **Figg WD**. Enhanced Activity of Estramustine, Vinblastine, Etoposide and Suramin in Prostate Carcinoma. *Neoplasma* 1999;46:117-23.
- 95 **Figg WD**, Pluda JM, Sartor O. Pentosan Polysulfate: A Polysaccharide that Inhibits Angiogenesis by Binding Growth Factors. In Teicher BA (Editor) Antiangiogenic Agents in Cancer Therapy. Published by Humana Press, Inc., Totowa, NJ, 1999;371-383.
- 96 Horti J, Dixon SC, Logothetis CJ, Guo Y, Reed E, **Figg WD**. Increased Transcriptional Activity of Prostate Specific Antigen in the Presence of TNP-470, An Angiogenesis Inhibitor. *Br J Cancer* 1999;79:1588-93.
- 97 **Figg WD**, Reed E, Green S, Pluda JM. Thalidomide, A Prodrug Inhibits Angiogenesis. In Teicher BA (Editor) Antiangiogenic Agents in Cancer Therapy. Published by Humana Press, Inc., Totowa, NY, 1999;407-22.

- 98 Kang MH, **Figg WD**, Dahut W. Taxanes in Hormone Refractory Prostate Cancer. *Cancer Pract* 1999;7:270-2.
- 99 Buckner JC, Malkin MG, Reed E, Cascino TL, Reid JM, Ames MM, Tong WPY, Lim S, **Figg WD**. Phase II Study of Antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in Patients with Recurrent Glioma. *Mayo Clin Proc* 1999;74:137-45.
- 100 Lush RM, Rudek MA, **Figg WD**. Review of Three New Agents that Target Angiogenesis, Matrix Metalloproteinases and Cyclin Dependent Kinases. *Cancer Control* 1999;6:459-465.
- 101 Melchior SW, Brown LG, **Figg WD**, Quinn JE, Santucci RA, Brunner J, Thuroff JW, Lange PH, Vessella RL. Effects of Phenylbutyrate on Proliferation and Apoptosis in Human Prostate Cancer Cells in vitro and in vivo. *Int J Oncology* 1999;14:501-8.
- 102 Bergan RC, Reed E, Myers CE, Headlee D, Brawley O, Cho HK, **Figg WD**, Tompkins A, Linehan WM, Kohler D, Steinberg SM, Blagosklonny MV. A Phase II Study of High Dose Tamoxifen in Patients with Hormone-Refractory Prostate Cancer. *Clin Cancer Res* 1999;5:2366-73.
- 103 Small EJ, Reese DM, Um B, Whisenant S, Dixon SC, **Figg WD**. Therapy for Advanced Prostate Cancer with Granulocyte Macrophage Colony - Stimulating Factor. *Clin Cancer Res* 1999;5:1738-44.
- 104 Sartor O, **Figg WD**. Current Management of Hormone Refractory Prostate Cancer. In Woods DP, Honn KV (Editors) The Oncobiology of the Prostate, Vol. 3. Published by JAI Press, Inc., Stamford, CT, 1999;235-256.
- 105 Senderowicz AM, Reid R, Headlee D, Abornathy T, Horti J, Lush RM, Reed E, **Figg WD**, Sausville E. A Phase II Trial of Gallium Nitrate in Patients with Androgen Metastatic Prostate Cancer. *Urol Int* 1999;63:120-5.
- 106 **Figg WD**, Raje S, Bauer KS, Tompkins A, Venzon D, Bergan R, Chen A, Hamilton M, Pluda J, Reed E. Pharmacokinetics of Thalidomide in an Elderly Prostate Cancer Population. *J Pharm Sci* 1999;88:121-5.
- 107 Cho HK, Lush RM, Bartlett DL, Alexander HR, Wu PC, Libutti SK, Lee KB, Venzon DJ, Bauer KS, Reed E, **Figg WD**. Pharmacokinetics of Cisplatin Administered by Continuous Hyperthermic Peritoneal Perfusion (CHPP) to Patients with Peritoneal Carcinomatosis. *J Clin Pharmacol* 1999;39:394-401.
- 108 Reed E, Matthews D, Dyer V, **Figg WD**. Meningeal Carcinomatosis in Metastatic Prostate Cancer: A Case Report. *The Prostate J* 1999;1:99-102.
- 109 **Figg WD**, Blumenfeld JR. Are We Making an Impact on Prostate Cancer? *Prostate Cancer and Prostatic Dis* 1999;2:60-61.
- 110 Dixon SC, Kruger EA, Bauer KS, **Figg WD**. Thalidomide Upregulates Prostate-Specific Antigen Secretion from LNCaP Cells. *Cancer Chemotherap Pharmacol* 1999;43:S78-84.
- 111 Sartor O, Rayford W, **Figg WD**. Management of Metastatic Prostate Cancer. In McConnell JD, Scardino PT (Editors) Atlas of Clinical Urology, Vol. II. The Prostate. Published by Current Medicine, Inc., Philadelphia, PA, 1999;15.1-15.14.
- 112 Park BJ, Brown CK, Hu Y, Alexander HR, Horti J, Raje S, **Figg WD**, Bartlett DL. Augmentation of Melanoma-Specific Gene Expression using a Tandem Melanocyte-specific Enhancer Results in Increased Cytotoxicity of the Purine Nucleoside Phosphorylase Gene in Melanoma. *Human Gene Therapy* 1999;10:889-98.

- 113 Cude KJ, Dixon SC, Guo Y, Lisella J, **Figg WD**. The Androgen Receptor: Genetic Considerations in the Development and Treatment of Prostate Cancer. *J Mol Medicine* 1999;77:419-26.
- 114 Luzzio FA, Piatt Zacherl D, **Figg WD**. A Facile Scheme for Phthalimide/Phthalimidine Conversion. *Tetrahedron Letters* 1999;40:2087-90.
- 115 Bauer KS, **Figg WD**, Hamilton JM, Jones EC, Premkumar A, Steinberg SM, Dyer V, Linehan WM, Pluda J, Reed E. A Pharmacokinetically Guided Phase II Study of Carboxyamido-triazole (CAI) in Androgen Independent Prostate Cancer. *Clin Cancer Res* 1999;5:2324-9.
- 116 Saif MW, **Figg WD**, Hewitt S, Brosky K, Reed E, Dahut W. Malignant Ascites as Only Manifestation of Metastatic Prostate Cancer. *Prostate Cancer Prostat Dis* 1999;2:290-3.
- 117 Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, **Figg WD**, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Vollmer R, Wilding G. Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen Independent Prostate Cancer: Recommendations from the Prostate-Specific Antigen Working Group. *J Clin Oncol* 1999;17:3461-7.
- 118 Erratum: Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen Independent Prostate Cancer: Recommendations from the Prostate-Specific Antigen Working Group. *J Clin Oncol* 2000;18:2644. Erratum: *J Clin Oncol* 2007;25:1154.
- 119 Kruger EA, Blagosklonny MV, Dixon SC, **Figg WD**. UCN-01, a Protein Kinase C Inhibitor, Inhibits Endothelial Cell Proliferation and Angiogenic Hypoxic Response. *Invasion Met* 2000;18:209-18.
- 120 Wilson WH, Sorbara L, **Figg WD**, Mont EK, Sausville E, Warren KE, Balis FM, Bauer K, Raffeld M, Senderowitz A, Monks A. Modulation of Clinical Drug Resistance in a B-Cell Lymphoma Patient by the Protein Kinase Inhibitor 7-Hydroxystaurosporine: Presentation of a Novel Therapeutic Paradigm. *Clin Cancer Res* 2000;6:415-21.
- 121 Bauer KS, Lush RM, Rudek MA, Shih C, Sausville E, **Figg, WD**. A High-Performance Liquid Chromatography Method using Ultraviolet and Fluorescence Detection for the Quantitation of UCN-01, 7-hydroxystaurosporine, from Human Plasma and Saliva. *Biomed Chromatogr* 2000;14:338-43.
- 122 Bauer KS, Cude KJ, Dixon SC, Kruger EA, **Figg WD**. Carboxyamido-Triazole Inhibits Angiogenesis by Blocking the Calcium-Mediated Nitric-Oxide Synthase-Vascular Endothelial Growth Factor Pathway. *J Pharmacol Exp Ther* 2000;292:31-7.
- 123 Kruger EA, Reed E, **Figg WD**. Thalidomide. In Rubanyi GM (Editor) Angiogenesis in Health and Disease. Published by Marcel Dekker Inc., New York, NY, 2000;359-376.
- 124 Blagosklonny MV, Dixon SC, **Figg WD**. Efficacy of Microtubule-active Drugs followed by Ketoconazole in Human Metastatic Prostate Cancer Cell Lines. *J Urol* 2000;163:1022-6.
- 125 Luzzio FA, Thomas EM, **Figg WD**. Thalidomide metabolites and analogs. Part II: Cyclic derivatives of 2-N-phthalimido-2S,3S (3-hydroxy) ornithine. *Tetrahedron Letters* 2000;41:7151-5.
- 126 Fine HA, **Figg WD**, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WKA. A Phase II Trial of the Anti-angiogenic Agent Thalidomide in Patients with Recurrent High Grade Gliomas. *J Clin Oncol* 2000;18:708-15.

- 127 Luzzio FA, Mayorov AV, **Figg WD**. Thalidomide Metabolites I: Derivatives of (+)-2-(N-Phthalimido)-gamma-hydroxyglutamic acid. *Tetrahedron Letters* 2000;41:2275-2278.
- 128 Kruger EA, Duray PH, Tsokos MG, Libutti S, Dixon SC, Rudek M, Pluda J, Allegra C, **Figg WD**. Endostatin Inhibits Microvessel Formation in the *ex vivo* Rat Aortic Ring Angiogenesis Assay. *Biochem Biophys Res Comm* 2000;268:183-91.
- 129 Rudek MA, March CL, Bauer KS, Pluda JM **Figg WD**. High-Performance Liquid Chromatography with Mass Spectrometry Detection for Quantitating COL-3, A Chemically modified Tetracycline, in Human plasma in Human. *J Pharmaceut Biomed Anal* 2000;22:1003-14.
- 130 Little RF, Wyvill KM, Pluda JM, Welles L, Marshall V, **Figg WD**. Newcomb FM, Tosato G, Feigal E, Steinberg SM, Whitby D, Goedert JJ, Yarchoan R. Activity of Thalidomide in AIDS-related Kaposi's Sarcoma. *J Clin Oncol* 2000;18:2593-602.
- 131 Berger AC, Alexander HR, Tang G, Wu PS, Hewitt SM, Turner E, Kruger E, **Figg WD**, Grove A, Kohn E, Stern D, Libutti SK. Endothelial Monocyte Activating Polypeptide II induces Endothelial Cell Apoptosis and May Inhibit Tumor Angiogenesis. *Microvascular Res* 2000;60:70-80.
- 132 Berger AC, Feldman AL, Gnant MFX, Kruger EA, Sim BKL, **Figg WD**, Alexander HR, Libutti SK. The Angiogenesis Inhibitor, Endostatin Does Not Effect Murine Cutaneous Wound Healing. *J Surg Res* 2000;91:26-31.
- 133 Messmann RA, Vitetta ES, Headlee D, Senderowicz AM, **Figg WD**, Schindler J, Michiel DF, Creekmore S, Steinberg SM, Kohler D, Jaffe E, Stetler-Stevenson M, Chen H, Ghetie V, Sausville EA. A Phase I study of combination therapy with immunotoxin IgG HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. *Clin Cancer Res* 2000;6:1302-13.
- 134 Kruger E, **Figg WD**. TNP-470: An Angiogenesis Inhibitor in Clinical Development for Cancer. *Exp Opin Investig Drugs* 2000;9:1383-1396.
- 135 Woo EW, Quinn M, **Figg WD**, Dahut W. The Use of Complementary and Alternative Medicine in Prostate Cancer Patients. *Oncol Issues* 2000;15:23-27.
- 136 Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, **Figg WD**, Zhou XP, Eng C, Spiegelman BM, Kantoff PW. Effects of Ligand Activation of peroxisome proliferators activated receptor γ on Human Prostate Cancer. *Proc Natl Acad Sci USA* 2000;97:10990-5.
- 137 Montgomery JS, **Figg WD**. The Essential Role of Apoptosis in Prostate Cancer Therapy. *Highlights in Oncol Pract* 2000;18:64-71.
- 138 Salnikow K, Costa M, **Figg WD**, Blagosklonny MV. Hyperinducibility of Hypoxia-Responsive Genes without p53/p21-dependent Checkpoint in Aggressive Prostate Cancer. *Cancer Res* 2000;60:5630-4.
- 139 Thrasher JB, Deeths J, Bennett C, Iyer P, Dineen MK, Zhai S, **Figg WD**, McLeod DG. Comparative Study of the Clinical Efficacy of Two Dosing Regimens of Flutamide. *Mol Urol* 2000;4:259-63.
- 140 Walther MM, Rehak NN, Venzon D, Myers CE, Linehan WM, **Figg WD**. Suramin Administration is Associated with a Decrease in Serum Calcium Levels. *World J Urol* 2000;18:388-91.

William Douglas Figg

Curriculum Vitae

Page 17 of 57

- 141 Blagosklonny MV, Dixon SC, Robey R, **Figg WD**. Resistance to growth inhibitory and Apoptotic Effects of Phorbol Ester and UCN01 in aggressive Cancer Cell Lines. *Int J Oncol* 2001;18:697-704.
- 142 Rochat B, Murray GI, **Figg WD**, McLeod HL. Human Cytochrome P450 1B1 and Anticancer Agent Metabolism: Mechanism for Tumor Specific Drug Inactivation? *J Pharmacol Exper Therapeut* 2001;296:537-41.
- 143 Montgomery JS, Price DK, **Figg WD**. The Androgen Receptor Gene and its Influence on the Development and Progression of Prostate Cancer. *J Pathology* 2001;195:138-46.
- 144 Chico I, Kang MH, Bergan R, Abraham J, Bakke S, Meadows B, Rutt A, Robey R, Choyke P, Merino M, Goldspiel B, Smith T, Steinberg S, **Figg WD**, Fojo T, Bates S. A Phase I Study of Infusional Paclitaxel in Combination with the p-glycoprotein Antagonist PSC833. *J Clin Oncol* 2001;19:832-42.
- 145 Dixon SC, Knopf KB, **Figg WD**. The Control of Prostate Specific Antigen Expression and Gene Regulation by Pharmacological Agents. *Pharmacol Rev* 2001;53:73-91.
- 146 Logothetis CJ, Wu KK, Finn LD, Daliani D, **Figg W**, Ghaddar H, Gutterman JU. Phase I Trial of the Angiogenesis Inhibitor TNP-470 for Progressive Androgen-independent Prostate Cancer. *Clin Cancer Res* 2001;7:1198-1203.
- 147 Bartlett DL, Libutti SK, **Figg WD**, Fraker DL, Alexander HR. Isolated Hepatic Perfusion for Unresectable Hepatic Metastases from Colorectal Cancer. *Surg* 2001;129:176-87.
- 148 Rudek MA, **Figg WD**, Dyer V, Dahut W, Turner ML, Steinberg SM, Liewehr DJ, Kohler DR, Pluda JM, Reed E. Phase I Clinical Trial of Oral COL-3, a Matrix Metalloproteinase Inhibitor, in Patients with Refractory Metastatic Cancer. *J Clin Oncol* 2001;19:584-92.
- 149 Burstein AH, Reed E, Tompkins AC, Venzon D, **Figg WD**. Phenylacetate Pharmacokinetics Based on Interactive Two-Stage Population Analysis. *Pharmacotherap* 2001;21:281-6.
- 150 Ghate JV, Turner ML, Rudek MA, **Figg WD**, Dahut W, Dyer V, Pluda JM, Reed E. Drug-Induced Lupus Associated with COL-3: A report of 3 cases. *Arch Dermatol* 2001;137:471-4.
- 151 **Figg WD**, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, Hamilton M, Parker C, Kruger EA, Pluda J, Dahut WL. A randomized phase II trial of docetaxel (Taxotere) plus thalidomide in androgen-independent prostate cancer. *Semin Oncol* 2001;28(Suppl 15):62-66.
- 152 Sunwoo JB, Herscher LL, Kroog GS, Thomas GR, Ondrey FG, Duffey DC, Solomon BI, Boss C, Albert PS, McCullugh L, Rudy S, Muir C, Zhai S, **Figg WD**, Cook JA, Mitchell JB, Van Waes C. Concurrent Paclitaxel and Radiation in the Treatment of Locally Advanced Head and Neck Cancer. *J Clin Oncol* 2001;19:800-11.
- 153 Sausville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM, Murgu A, **Figg WD**, Lahusen T, Jaken S, Jing XX, Roberge M, Fuse E, Kuwabara T, Senderowicz AM. Phase I Trial of 72 hour Continuous Infusion UCN-01 in Patients with Refractory Neoplasms. *J Clin Oncol* 2001;19:2319-2333.
- 154 Dahut WD, Fedenko KM, Noone M, Arlen P, Gulley J, Pluda J, **Figg WD**. A Randomized Phase II Trial of Docetaxel plus Thalidomide in Androgen-Independent Prostate Cancer. *Adv Prostate Cancer* 2001;5:8-10.

- 155 **Figg WD**, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, Jones E, Premkumar A, Linehan WM, Floeter MK, Chen CC, Dixon SC, Kohler DR, Kruger E, Gubish E, Pluda JM, Reed E. A Randomized Phase II Trial of Thalidomide, An Angiogenesis Inhibitor, in Patients with Androgen Independent Prostate Cancer. *Clin Cancer Res* 2001;7:1888-93.
- 156 Woo EW, Messmann R, Sausville EA, **Figg WD**. Quantitative Determination of Perifosine, a Novel Alkylphosphocholine Anticancer Agent, in Human Plasma by Reversed-Phase Liquid Chromatography - Electrospray Mass Spectrometry. *J Chromatogr B* 2001;759:247-57.
- 157 Molloy FM, Floeter MK, Syed NA, Sandbrink F, Culcea E, Steinberg SM, Dahut W, Pluda J, Kruger EA, Reed E, **Figg WD**. Thalidomide neuropathy in patients treated for metastatic prostate cancer. *Muscle Nerve* 2001;24:1050-7.
- 158 Rudek MA, Horne M, **Figg WD**, Dahut W, Dyer V, Pluda JM, Reed E. Reversible Sideroblastic Anemia Associated with the Tetracycline Analog COL-3. *Am J Hematol* 2001;67:51-3.
- 159 Kang MH, **Figg WD**, Ando Y, Blagosklonny MV, Liewehr D, Fojo T, Bates SE. The p-glycoprotein antagonist PSC 833 increases the Plasma concentrations of 6 alpha-hydroxypaclitaxel, a Major Metabolite of Paclitaxel. *Clin Cancer Res* 2001;7:1610-7.
- 160 Kohn EC, Reed E, Sarosy GA, Minasian L, Bauer KS, Bostick-Bruton F, Kulpa V, Fuse E, Tompkins A, Noone M, Goldspiel B, Pluda J, **Figg WD**, Liotta LA. A Phase I Trial of Carboxyamido-triazole and Paclitaxel for Relapsed Solid Tumors: Potential Efficacy of the Combination, and Demonstration of Pharmacokinetic Interaction. *Clin Cancer Res* 2001;7:1600-9.
- 161 Kruger EA, **Figg WD**. Protein Binding Alters the Activity of Suramin, Carboxyamidotriazole, and UCN-01 in an ex vivo Rat Aortic Ring Angiogenesis Assay. *Clin Cancer Res* 2001;7:1867-72.
- 162 Kruger EA, Duray PH, Price DK, Pluda JM, **Figg WD**. Approaches to Preclinical Screening Antiangiogenic Agents. *Sem Oncol* 2001;28:570-576.
- 163 Bates S, Kang M, Meadows B, Bakke S, Meadows B, Choyke P, Merino M, Goldspiel B, Chico I, Smith T, Chen C, Robey R, Bergan R, **Figg WD**, Fojo T. A Phase I Study of Infusional Vinblastine in Combination with the Pgp Antagonist PSC 833 (Valdospar). *Cancer* 2001;92:1577-1590.
- 164 Chang E, Alexander HR, Libutti SK, Hurst R, Zhai S, **Figg WD**, Bartlett DL. Laparoscopic Continuous Hyperthermic Peritoneal Perfusion. *J Am College of Surg* 2001;193:225-9
- 165 Gore SD, Weng LJ, Zhai S, **Figg WD**, Donehower RC, Dover GJ, Grever M, Griffin CA, Grochow LB, Rowinsky EK, Zabalena Y, Hawkins AL, Burks K, Miller CB. Impact of the Putative Differentiating Agent Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute Myeloid Leukemia. *Clin Cancer Res* 2001;7:2330-9.
- 166 Carrasquillo JA, Whatley M, Dyer V, **Figg WD**, Dahut W. Alendronate does not interfere with 99m TC-methylene diphosphonate bone scanning. *J Nucl Med* 2001;42:1359-63.
- 167 Blagosklonny MV, Fojo T, Bhalla KN, Kim JS, Trepel JB, **Figg WD**, Rivera Y, Neckers L. The Hsp90 Inhibitor Geldanamycin Selectively Sensitizes Bcr-Abl-expressing Leukemia Cells to Cytotoxic Chemotherapy. *Leukemia* 2001;15:1537-43.
- 168 Gilbert J, Baker SD, Bowling MK, Grochow L, **Figg WD**, Zabalena Y, Donehower RC, Carducci MA. A Phase I Dose Escalation and Bioavailability Study of Oral Sodium Phenylbutyrate in Patients with Refractory Solid Tumor Malignancies. *Clin Cancer Res* 2001;7:2292-2300.

- 169 Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, **Figg WD**, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak D, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Vollmer R, Wilding G. Update: Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer. *Classic Papers and Current Comments* 2001;6:311-7.
- 170 Schrupp DS, Zhai S, Nguyen DM, Weiser TS, Fisher BA, Terrill RE, Flynn BM, Duray PH, **Figg WD**. Pharmacokinetics of Paclitaxel Administered by Hyperthermic Retrograde Isolated Lung Perfusion Techniques. *J Thorac and Cardiovascul Surg* 2002;123:686-694.
- 171 Arlen PM, **Figg WD**, Gulley J, Cox MC, Linehan WM, Dahut W. National Cancer Institute Intramural Approach to Advanced Prostate Cancer. *Clin Prostate Cancer* 2002;1:153-62.
- 172 Cianfrocca M, Cooley TP, Lee JY, Rudek MA, Scadden DT, Ratner L, Pluda JM, **Figg WD**, Krown SE, Dezube BJ. Matrix Metalloproteinase Inhibitor COL-3 in the Treatment of AIDS-Related Kaposi's Sarcoma: A Phase I AIDS Malignancy Consortium Study. *J Clin Oncol* 2002;20:153-159.
- 173 Bates SF, Chen C, Robey R, Kang M, **Figg WD**, Fojo T. Reversal of Multidrug Resistance: Lessons from Clinical Oncology. *Novartis Found Symp.* 2002;243:83-96; discussion 96-102, 180-5.
- 174 Kaur M, Reed E, Sartor O, Dahut W, **Figg WD**. Suramin's Development: What Did We Learn? *Invest New Drugs* 2002;20:209-219.
- 175 **Figg WD**, Kruger EA, Kim S, Price DK, and Dahut WD. Inhibition of Angiogenesis: Treatment Options for Patients with Metastatic Prostate Cancer. *Invest New Drugs* 2002;20:183-94.
- 176 Price DK, Ando Y, Kruger EA, Weiss M, **Figg WD**. 5'-OH- Thalidomide, a Metabolite of Thalidomide, Inhibits Angiogenesis. *Therapeut Drug Monitoring* 2002;24:104-10.
- 177 Macpherson GR, Ng SS, Lakhani NJ, Price DK, Venitz J, **Figg WD**. Antiangiogenesis Therapeutic Strategies in Prostate Cancer. *Cancer Metastasis Rev* 2002;21:93-106.
- 178 Cude KJ, Montgomery JS, Price DK, Dixon SC, Kincaid RL, Kovacs KF, Venzon D, Leiwher DJ, Johnson ME, Reed E, **Figg WD**. The Role of an Androgen Receptor Polymorphism in the Clinical Outcome of Patients with Metastatic Prostate Cancer. *Urol Int* 2002;68:16-23.
- 179 Ando Y, Fuse E, **Figg WD**. Thalidomide Metabolism by CYP2C subfamily. *Clin Cancer Res* 2002;8:1964-73.
- 180 Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, **Figg WD**, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE. Phase I Trial of the Histone Deacetylase Inhibitor, Depsipeptide (FR901228, NSC 630176), in Patients with Refractory Neoplasms. *Clin Cancer Res* 2002;8:718-28.
- 181 Zhai S, Senderowicz AM, Sausville EA, **Figg WD**. Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Clinical Development. *Annals Pharmacother* 2002;36:905-11.
- 182 Zhai S, Sausville E, **Figg WD**. A High Performance Liquid Chromatography Method Using Ultraviolet Detection for the Quantitation of Flavopiridol from Human Plasma. *Biomedical Chromatogr* 2002;16:379-82.

- 183 Gore SD, Weng LJ, **Figg WD**, Zhai S, Donehower RC, Dover G, Grever MR, Griffin C, Grochow LB, Hawkins A, Burks K, Zabelena Y, Miller CB. Impact of Prolonged Infusions of the Putative Differentiating Agent Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute Myeloid Leukemia. *Clin Cancer Res* 2002;8:963-970.
- 184 Neelapu S, **Figg WD**, Reed E. Leptomeningeal Carcinomatosis in Metastatic Prostate Cancer. *Southern Med J* 2002;95:107-8.
- 185 Beliveau R, Gingras D, Kruger EA, Lamy S, Sirois P, Simard B, Sirois MG, Tranqui L, Baffert F, Beaulieu E, Dimitriadou V, Pepin MC, Courjal F, Ricard I, Poyet P, Falardeau P, **Figg WD**, Dupont E. The Antiangiogenic Agent Neovastat (AE-941) Inhibits Vascular Endothelial Growth Fractor-mediated Biological Effects. *Clin Cancer Res* 2002;8:1242-50.
- 186 Bennett CL, Price DK, Kim S, Liu D, Nathan D, Johnson ME, Montgomery JS, Cude K, Brockbank JC, Sartor O, **Figg WD**. Racial Variation in CAG repeat lengths within the Androgen Receptor gene among Prostate Cancer Patients of Lower Socioeconomic Status. *J Clin Oncol* 2002;20:3599-604.
- 187 Ando Y, **Figg WD**. Irinotecan in Small-Cell Lung Cancer. *New Engl J Med* (letter) 2002;346:1414-5.
- 188 Rudek MA, Venitz J, **Figg WD**. Matrix Metalloproteinase Inhibitors: Do they have a Place in the Anticancer Therapy? *Pharmacotherapy* 2002;22:705-720.
- 189 Ng SS, Brown M, **Figg WD**. Thalidomide, an Antiangiogenic Agent with Clinical Activity in Cancer. *Biomed Pharmacother* 2002;56:194-9.
- 190 Gulley J, **Figg WD**, Dahut WD. Docetaxel plus Thalidomide in a Patient with Androgen-Independent Prostate Cancer: Case Report. *Case Studies in Prostate Cancer* 2002;3:1-7.
- 191 Liu Y, **Figg WD**. Antiangiogenesis: Does it Have a Role in the Treatment of Metastatic Prostate Cancer? *Adv in Prostate Cancer* 2002;6:10-14.
- 192 Schrupp DS, Nguyen DM, Kunst TE, Hancox A, **Figg WD**, Steinberg SM, Pishchik V, Becerra Y. Phase I Study of Sequential Deoxyazacytidine/Depsipeptide Infusion in Patients with Malignancies Involving Lungs or Pleura. *Clin Lung Cancer* 2002;4:186-92.
- 193 Ando Y, Price DK, Dahut WL, Cox MC, Reed E, **Figg WD**. Pharmacogenetic Associations of CYP2C19 Genotype with in vivo Metabolisms and Pharmacological Effects of Thalidomide. *Cancer Bio Ther* 2002;1:669-73.
- 194 Marshall JL, Rizvi N, Kauh J, Dahut W, Figuera M, Kang MH, **Figg WD**, Wainer I, Chaissang C, Li MZ, Hawkins WJ. A Phase I trial of Depsipeptide (FR901228) in patients with Advanced Cancer. *J Experimental Therap Oncol* 2002;2:325-32.
- 195 Blagosklonny MV, Darzynkiewicz Z, **Figg WD**. Flavopiridol Inversely Affects p21(WAF1/CIP1) and p53 and Protects p21-Sensitive Cells from Paclitaxel. *Cancer Biol Ther* 2002;1:420-5.
- 196 Tan AR, Headlee D, Messmann R, Sausville EA, Arbuck SG, Murgu AJ, Melillo G, Zhai S, **Figg WD**, Swain SM, Senderowicz AM. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. *J Clin Oncol* 2002;20:4074-82.
- 197 Zogakis TG, Costouros NG, Kruger EA, Forbes S, He M, Qian M, Feldman AL, **Figg WD**, Alexander HR, Liu ET, Kohn EC, Libutti SK. Microarray gene expression profiling of angiogenesis inhibitors using the rat aortic ring assay. *Biotechniques* 2002;33:664-70.

- 198 Messmann RA, Ullmann CD, Lahusen T, Kalehua A, Wasfy J, Melillo G, Ding I, Headlee D, **Figg WD**, Sausville EA, Senderowicz AM. Flavopiridol-related Pro-inflammatory Syndrome Associated with Induction of Interleukin-6. *Clin Cancer Res* 2003;9:562-570.
- 199 Zhai S, Sausville EA, Senderowicz AM, Ando Y, Headlee D, Messmann RA, Arbuck S, Murgo A, Melillo G, Fuse E, **Figg WD**. Clinical Pharmacology and Pharmacogenetics of Flavopiridol 1-Hour IV Infusion in Patients with Refractory Neoplasms. *AntiCancer Drugs* 2003;14:125-35.
- 200 Fine HA, Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, **Figg WD**, Purow BJ, Borkowf C. A Phase II Trial of Thalidomide and Carmustine for Patients with Recurrent High Grade Gliomas. *J Clin Oncol* 2003;21:2299-304.
- 201 Macpherson GR, Franks M, Tomoia-Cotisel A, Ando Y, Price DK, **Figg WD**. Current status of thalidomide and its role in the treatment of metastatic prostate cancer. *Critical Rev Oncol Hematol* 2003;46:Suppl 49-57.
- 202 Gulley JG, **Figg WD**, Dahut WL. Treatment options for Androgen Independent Prostate Cancer. *Clin Adv in Hematol and Oncol* 2003;1:49-57.
- 203 Lakhani NJ, Sarkar MA, Venitz J, **Figg WD**. 2-Methoxyestradiol, A Promising Anticancer Agent. *Pharmacotherapy* 2003;23:165-72.
- 204 Uchio EM, Linehan WM, **Figg WD**, Walther MM. A Phase I Study of Intravesical Suramin for the Treatment of Superficial Transitional Cell Carcinoma of the Bladder. *J Urol* 2003;169:357-60.
- 205 Horne MK 3rd, **Figg WD**, Arlen P, Gulley J, Parker C, Lakhani N, Parnes H, Dahut WL. Increased Frequency of Venous Thromboembolism with the Combination of Docetaxel and Thalidomide in Patients with Metastatic Androgen Independent Prostate Cancer. *Pharmacotherapy* 2003;23:315-8.
- 206 Hamilton M, Dahut W, Brawley O, Davis P, Wells-Jones T, Kohler D, Duray P, Liewehr DJ, Lakhani N, Steinberg SM, **Figg WD**, Reed E. A Phase I/II Study of High-Dose Tamoxifen in Combination with Vinblastine in Patients with Androgen Independent Prostate Cancer. *Acta Oncol* 2003;42:195-201.
- 207 Leonard GD, Dahut WL, Gulley J, Arlen P, **Figg WD**. Docetaxel and Thalidomide as a Treatment Option in Androgen Independent Non-metastatic Prostate Cancer. *Rev Urol* 2003;5(Suppl 3):S65-70.
- 208 Sparreboom A, Danesi R, Ando Y, Chan J, **Figg WD**. Pharmacogenomics of ABC Transporters and its Role in Cancer Chemotherapy. *Drug Resistance Updat* 2003;6:71-84.
- 209 Rudek MA, Bauer KS, Lush RM, Stinson SF, Senderowicz AM, Headlee DJ, Arbuck SG, Cox MC, Murgo AJ, Sausville EA, **Figg WD**. Clinical Pharmacology of Flavopiridol Following a 72-Hour Continuous Infusion. *Ann Pharmacother* 2003;37:1369-74.
- 210 Kurdziel KA, **Figg WD**, Carrasquillo JA, Huebsch S, Whatley M, Sellers D, Libutti SK, Pluda JM, Dahut W, Reed E, Bacharach SL. Using Positron Emission Tomography 2-Deoxy-2-[18F] Fluro-D-Glucose, 11CO, and 15O-water for Monitoring Androgen Independent Prostate Cancer. *Mol Imaging Biol* 2003;5:86-93.
- 211 Luzzio FA, Mayorov AV, Ng SS, Kruger EA, **Figg WD**. Thalidomide Metabolites and Analogs. Part 3: Synthesis and Antiangiogenic Activity of the Teratogenic and TNFalpha-Modulatory Thalidomide Analog 2-(2,6-Dioxopiperidine-3-yl)phthalimidine. *J Med Chem* 2003;46:3793-9.

- 212 Rudek MA, Venitz J, Ando Y, Reed E, Pluda JM, **Figg WD**. Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies. *J Clin Pharmacol* 2003;43:1124-35.
- 213 Ng SS, Gutschow M, Weiss M, Hauschildt S, Teubert U, Hecker TK, Luzzio FA, Kruger EA, Eger K, **Figg WD**. Antiangiogenic Activity of N-Substituted and Tetrafluorinated Thalidomide Analogues. *Cancer Res* 2003;63:3189-94.
- 214 Macpherson GR, Ng SS, Forbes SL, Melillo G, Karpova T, McNally J, Conrads TP, Veenstra TD, Martinez A, Cuttitta F, Price DK, **Figg WD**. Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay. *Mol Cancer Ther* 2003;2:845-54.
- 215 Lakhani NJ, Venitz J, **Figg WD**, Sparreboom A. Pharmacogenetics of Estrogen Metabolism and Transport in Relation to Cancer. *Curr Drug Metab* 2003;4:505-13.
- 216 Ng SS, **Figg WD**. Antitumor Activity of Herbal Supplements in Human Prostate Cancer Xenografts Implanted in Immunodeficient Mice. *Anticancer Res* 2003;23:3585-90.
- 217 Acharya MR, Venitz J, **Figg WD**, Sparreboom A. Chemically Modified Tetracyclines as Matrix Metalloproteinase Inhibitors in Anti-Cancer Drug Development. In Mohan RM (Editor) Research Advances in Cancer, Vol 3, Part II, 2003. Published by Global Research Network, Kerala, India.
- 218 Lepper ER, Swain SM, Tan AR, **Figg WD**, Sparreboom A. Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor. *J Chromatogr B* 2003;796:181-8.
- 219 **Figg WD**, Cox MC. Pharmacy Education: Back to the Basics? *Pharmacotherapy* 2003;23:1381-90.
- 220 **Figg WD**, Cox MC. Pharmacy Education: Authors Response. *Pharmacotherapy* 2004;24:691-3.
- 221 Passaro MD, Piquion J, Mullen N, Sutherland D, Zhai S, **Figg WD**, Blye R, Nieman LK. Luteal phase dose-response relationships of the antiprogestin CDB-2914 in normally cycling women. *Hum Reprod* 2003;18:1820-1827.
- 222 ten Tije AJ, Loos WJ, Verweij J, Baker SD, Dinh K, **Figg WD**, Sparreboom A. Disposition of polyoxyethylated excipients in humans: Implications for drug safety and formulation approaches. *Clin Pharmacol Ther* 2003;74:509-10.
- 223 Retter AS, **Figg WD**, Dahut WL. The Combination of Antiangiogenic and Cytotoxic Agents in the Treatment of Prostate Cancer. *Clin Prostate Cancer* 2003;2:153-9.
- 224 Hussain MM, Kotz H, Minasian L, Premkumar A, Sarosy G, Reed E, Zhai S, Steinberg S, Raggio M, Oliver VK, **Figg WD**, Kohn EC. A Phase II Trial of Carboxyamido-triazole in Patients with Relapsed Epithelial Ovarian Cancer. *J Clin Oncol* 2003;21:4356-63.
- 225 Macpherson GR, Ng SSW, Lakhani NJ, Price DK, Venitz J, **Figg WD**. Anti-angiogenesis Therapeutic Strategies in Prostate Cancer. In Cher ML, Honn KV, Raz A (Editors) Prostate Cancer: New Horizons in Research and Treatment. Published by Kluwer Academic Publishing, New York, NY, 2003, 317-331.
- 226 Franks ME, Macpherson GR, Lepper ER, **Figg WD**, Sparreboom A. New Directions in Cancer Research 2003: Technological Advances in Biology, Drug Resistance, and Molecular Pharmacology. *Drug Resist Updat* 2003;6:301-12.

- 227 Sparreboom A, Cox MC, Acharya MR, **Figg WD**. Herbal Remedies in the United States Potential Adverse Interactions with Anticancer Agents. *J Clin Oncol* 2004;22:2489-503.
- 228 Price DK, Franks ME, **Figg WD**. Genetic Variations in the Vitamin D Receptor, Androgen Receptor and Enzymes that Regulate Androgen Metabolism. *J Urol* 2004;171:S45-49.
- 229 Ehrlich A, Booher S, Becerra Y, Borris DL, **Figg WD**, Turner ML, Blauvelt A. Micellar Paclitaxel Improves Severe Psoriasis in a Prospective Phase II Pilot Study. *J Am Acad of Derm* 2004;50:533-40.
- 230 Chan LW, Moses MA, Goley E, Sproull M, Muanza T, Coleman CN, **Figg WD**, Albert PS, Menard C, Camphausen K. Urinary VEGF and MMP levels as Predictive Markers of 1-year Progression-free Survival in Cancer Patients Treated with Radiation Therapy: A longitudinal Study of Protein Kinetics throughout Tumor Progression and Therapy. *J Clin Oncol* 2004;22:499-506.
- 231 Franks ME, Macpherson GR, **Figg WD**. Thalidomide. *Lancet* 2004;363:1802-11.
- 232 **Figg WD**, McLeod HL (Editors) Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. Published by Humana Press, Totowa, NJ, 2004.
- 233 Acharya MR, **Figg WD**. Book Review: Handbook of Pharmaceutical Biotechnology. *Annals of Pharmacotherapy* 2004;38:178.
- 234 Ng SS, **Figg WD**, Sparreboom A. Taxane-Mediated Antiangiogenesis In Vitro: Influence of Formulation Vehicles and Binding Proteins. *Cancer Res* 2004;64:821-4.
- 235 Tohnya TM, Ng SS, Dahut WL, Wright JJ, Arlen PM, Gulley JL, Parker C, Zeldis J, **Figg WD**. A Phase I Study of Oral CC-5013 (lenalidomide, Revlimid), a Thalidomide Derivative, in Patients with Refractory Metastatic Cancer. *Clin Prostate Cancer* 2004;2:241-3.
- 236 Cox MC, **Figg WD**, Thurman PW. No Rational Theory for Drug Pricing. *J Clin Oncol* 2004;22:962-3.
- 237 Hwang K, Acharya MR, Sausville EA, Zhai S, Woo EW, **Figg WD**, Sparreboom A. Determination of MS-275, a Novel Histone Deacetylase Inhibitor, in Human Plasma by Liquid Chromatography-Electrospray Mass Spectrometry. *J Chromatogr B* 2004;804:289-94.
- 238 McDonald DM, Teicher BA, Stetler-Stevenson W, Ng SS, **Figg WD**, Folkman J, Hanahan D, Auerbach R, O'Reilly M, Herbst R, Cheresch D, Gordon M, Eggermont A, Libutti SK. Report from the Society for Biological Therapy and Vascular Biology Faculty of the NCI Workshop on Angiogenesis Monitoring. *J Immunotherapy* 2004;27:161-175.
- 239 Luzzio FA, **Figg WD**. Thalidomide Analogues: Derivatives of an Orphan Drug with Diverse Biological Activity. *Expert Opinion on Therapeutic Patents* 2004;14:215-29.
- 240 **Figg WD**, Franks ME, Venzon D, Duray P, Cox MC, Linehan WM, Van-Bingham W, Eastham JA, Reed E, Sartor O. Gleason Score and Pretreatment PSA in Survival Among Patients with Stage D2 Prostate Cancer. *World J Urol* 2004;22:425-30.
- 241 Tan AR, Yang X, Hewitt SM, Berman A, Lepper ER, Parr AL, **Figg WD**, Chow C, Steinberg SM, Bacharach SL, Whatley M, Carrasquillo JA, Brahim JS, Ettenberg SA, Lipkowitz S, Swain SM. Evaluation of Biologic End Points and Pharmacokinetics in Patients with Metastatic Breast Cancer after Treatment with Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. *J Clin Oncol*, 2004;22:3080-90.

William Douglas Figg

Curriculum Vitae

Page 24 of 57

- 242 Lepper ER, Ng SS, Gutschow M, Weiss M, Hauschildt S, Hecker TK, Luzzio FA, Eger K, **Figg WD**. Comparative Molecular Field Analysis and Comparative Molecular Similarity Indices Analysis of Thalidomide Analogues as Angiogenesis Inhibitors. *J Med Chem* 2004;47:2219-27.
- 243 Tohnya TM, Kim S, Fine HA, Dunn L, **Figg WD**, Sparreboom A. Determination of SU5416, a Novel Angiogenesis Inhibitor, in Human Plasma by Liquid Chromatography. *J Chromatogr B* 2004;805:135-40.
- 244 Singh A, **Figg WD**. Upregulation of the Androgen Receptor During Prostate Cancer Progression. *Cancer Biol Therapy* 2004;3:284-5.
- 245 Lepper ER, Hicks JK, Verweij J, Zhai S, **Figg WD**, Sparreboom A. Determination of Midazolam in Human Plasma by liquid chromatography with mass-spectrometric detection. *J Chromatogr B* 2004;806:305-10.
- 246 Lakhani NJ, Sparreboom A, Dahut WL, Venitz J, **Figg WD**. Determination of the Antiangiogenesis Agent 2-Methoxyestradiol (2ME2) in Human Plasma by Liquid Chromatography with Ultraviolet Detection. *J Chromatogr B* 2004;806:289-93.
- 247 Ng SS, Macpherson GR, Gutschow M, Eger K, **Figg WD**. Antitumor Effects of Thalidomide Analogs in Human Prostate Cancer Xenografts Implanted in Immunodeficient Mice. *Clin Cancer Res* 2004;10:4192-7.
- 248 Acharya MR, Baker SD, Verweij J, **Figg WD**, Sparreboom A. Determination of fraction unbound docetaxel using microequilibrium dialysis. *Anal Biochem* 2004;331:192-4.
- 249 Acharya MR, Venitz J, **Figg WD**. What Dose do you Start with and How Quickly do you Increase that Dose? *Am Pharmaceutic Outsourcing* 2004;5:1-4.
- 250 Cox MC, Smith NF, **Figg WD**. The Use of Thalidomide in Renal Cancer. *American Society of Clinical Oncology 2004 Educational Book* 2004;249-51
- 251 Price DK, **Figg WD**. H-Tert-Immortalized Endothelial Cells: An Important New Research Tool. *Cell Cycle* 2004;3:789.
- 252 Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, Wright JJ, Parnes H, Chen CC, Jones E, Parker CE, Linehan WM, **Figg WD**. A Randomized Phase II Trial of Docetaxel plus Thalidomide in Androgen-Independent Prostate Cancer. *J Clin Oncol* 2004;22:2532-9.
- 253 Bates SE, Bakke S, Kang M, Robey RW, Zhai S, Thambi P, Chen CC, Patil S, Smith T, Steinberg SM, Merino M, Goldspiel B, Meadows B, Stein WD, Choyke P, Balis F, **Figg WD**, Fojo T. A Phase I/II Study of Infusional Vinblastine with the P-Glycoprotein Antagonist Valspodar (PSC-833) in Renal Cell Carcinoma. *Clin Cancer Res* 2004;10:4724-33.
- 254 Tan AR, Yang X, Berman A, Zhai S, Sparreboom A, Parr AL, Chow C, Brahim JS, Steinberg SM, **Figg WD**, Swain SM. Phase I Trial of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination with Docetaxel in Patients with Metastatic Breast Cancer. *Clin Cancer Res* 2004;10:5038-47.
- 255 Cox M, Liu Y, **Figg WD**. Antiangiogenesis in Prostate Cancer. *Cancer Therapy* 2004;2:121-9.
- 256 Acharya MR, Venitz J, **Figg WD**, Sparreboom A. Chemically modified Tetracyclines as Inhibitors of Matrix Metalloproteinases. *Drug Resist Updat* 2004;7:195-208.

- 257 Paoluzzi L, **Figg WD**. Histone Deacetylase Inhibitors are Potent Radiation Protectants. *Cancer Biol Ther* 2004;3:612-3.
- 258 Macpherson G, **Figg WD**. Small molecule-mediated anti-cancer therapy via hypoxia inducible factor-1 blockade. *Cancer Biol Ther* 2004;3:503-4.
- 259 Paoluzzi L, Singh AS, Price DK, Danesi R, Mathijssen RH, Verweij J, **Figg WD**, Sparreboom A. Influence of genetic variants in *UGT1A1* and *UGT1A9* on the *in vivo* glucuronidation of SN-38. *J Clin Pharmacol* 2004;44:854-60.
- 260 Hwang K, Piekarz RL, Bates SE, **Figg WD**, Sparreboom A. Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatography-mass spectrometry. *J Chromatogr B* 2004;809:81-86.
- 261 Price DK, **Figg WD**. Mutations in the EGFR: The Importance of Genotyping. *Cancer Bio Ther* 2004;3:434-5.
- 262 Mathijssen RHJ, De Jong FA, Van Schaik RHN, Lepper ER, Friberg L, Rietveld T, De Bruijn P, Graveland WJ, **Figg WD**, Verweij J, Sparreboom A. Prediction of Irinotecan Pharmacokinetics by use of Cytochrome P4503A4 Phenotyping Probes. *J Natl Canc Inst*, 2004;96:1585-92.
- 263 Sparreboom A, Chen H, Acharya MR, Senderowicz AM, Messmann RA, Kuwabara T, Venzon D, Margo A, Headlee D, Sausville EA, Effects of Alpha1-Acid Glycoprotein on the Clinical Pharmacokinetics of 7-hydroxystaurosporine. **Figg WD**. *Clin Cancer Res* 2004;10:6840-6.
- 264 Ng SSW, **Figg WD**. Upregulation of Endogenous Angiogenesis Inhibitors: A Mechanism of Action of Metronomic Chemotherapy. *Cancer Biol Therapy* 2004;3:1212-3.
- 265 Acharya MR, **Figg WD**. Histone deacetylase inhibitor enhances the anti-leukemic activity of an established nucleoside analogue. *Cancer Bio Therapy* 2004;3:719-20.
- 266 Tohnya TM, Hwang K, Lepper ER, Fine HA, Dahut WL, Venitz J, Sparreboom A, **Figg WD**. Determination of CC-5013, a Thalidomide Analogue, in Human plasma by liquid Chromatography-mass Spectrometry. *J Chromatogr B* 2004;811:135-41.
- 267 Smith NF, **Figg WD**, Sparreboom A. Recent Advances in Pharmacogenetic Approaches to Anti-Cancer Drug Development. *Drug Develop Res* 2004;51:1-21.
- 268 Retter AS, **Figg WD**, Dahut WL. A Case Study of Docetaxel and Thalidomide in Androgen Independent Prostate Cancer. *Am J of Oncol Rev* 2004;3:618-21.
- 269 Cox MC, Lepper ER, **Figg WD**, Sparreboom A. Use of St. John's Wort by Cancer Patients: Novel Insights and Safety Considerations. *J Cancer Integrative Med* 2004;2:125-136.
- 270 Macpherson GR, Singh A, Bennett C, Venzon D, Liewehr D, Franks M, Dahut B, Price DK, **Figg WD**. Genotypic and functional analysis of the D104N variant of Human Endostatin. *Cancer Bio Therap* 2004;3:1298-303.
- 271 Tohnya TM, **Figg WD**. Immunomodulation of Multiple Myeloma. *Cancer Bio Therapy* 2004;3:1060-1.
- 272 Baker SD, Li J, ten Tije AJ, **Figg WD**, Graveland W, Verweij J, Sparreboom A. Relationship of systemic Exposure to Unbound Docetaxel and Neutropenia. *Clin Pharmacol Ther* 2005;77:43-53.

- 273 **Figg WD**, Liu Y, Arlen P, Gulley J, Steinberg SM, Liewehr DJ, Cox MC, Zhai S, Cremers S, Parr A, Yang X, Chen CC, Jones E, Dahut WL. A Randomized Phase II Trial of Ketoconazole Plus Alendronate versus Ketoconazole Alone in Patients with Androgen-Independent Prostate Cancer and Bone Metastases. *J Urol* 2005;173:790-6.
- 274 Gulley JL, **Figg WD**, Steinberg SM, Carter J, Hussain M, Dahut WL. A Prospective Analysis of the Time to Normalization of Serum Androgens Following 6 Months of Androgen Deprivation Therapy in Patients on a Randomized Phase III Clinical Trial Using Limited Hormonal Therapy. *J Urol* 2005;173:1567-71.
- 275 Longoria RL, Cox MC, **Figg WD**. Antiangiogenesis: Possible Treatment Option for Prostate Cancer? Clinical Prostate Cancer. *Clin Prostate Cancer* 2005;4:197-202.
- 276 Cox MC, Permenter M, **Figg WD**. Angiogenesis in Prostate Cancer: Important Laboratory and Clinical Findings. *Cur Oncol Rep* 2005;7:215-9.
- 277 Singh A, **Figg WD**. In Vivo Models of Prostate Cancer Metastasis to Bone. *J Urol* 2005;174:820-6.
- 278 Singh AS, Price DK, **Figg WD**. Polymorphisms in the Androgen Receptor and Genes that Metabolize Androgens in the Development of Prostate Cancer. *Nature Clin Pract Urol* 2005;2:101-107.
- 279 Palmieri D, Halverson D, Ouatas T, Horak C, Salerno M, Johnson J, **Figg WD**, Hollingshead M, Hursting S, Berrigan D, Steinberg SM, Merino MJ, Steeg PS. Medroxyprogesterone acetate Elevation of Nm 23-H1 Metastasis Suppressor Expression in Hormone Receptor-Negative Breast Cancer. *J Natl Cancer Inst* 2005;97:632-42.
- 280 Scripture CD, **Figg WD**, Sparreboom A. Paclitaxel Chemotherapy: From Empiricism Toward a Mechanism based Formulation Strategy. *Ther Clin Risk Management* 2005;1:107-14.
- 281 Fuse E, Kuwabara T, Sparreboom A, Sausville EA, **Figg WD**. A Review of UCN-01 Development: A Lesson in the Importance of Clinical Pharmacology. *J Clin Pharmacology* 2005;45:394-403.
- 282 Lepper ER, Nooter K, Verweij J, Acharya M, **Figg WD**, Sparreboom A. Mechanisms of Resistance to Anticancer Drugs: the role of the Polymorphic ABC Transporters ABCB1 and ABCG2. *Pharmacogenomics* 2005;6:115-38.
- 283 Cox MC, **Figg WD**. Book Review: Management of Prostate Cancer. *Annals of Pharmacotherapy* 2005;39: 390-1.
- 284 Sparreboom A, Scripture CD, Trieu V, William PJ, De T, Yang A, Beals B, **Figg WD**, Hawkins MJ, Desai N, Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Protein-Stabilized, Nanoparticle Formulation of Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol). *Clin Cancer Res* 2005;11:4136-43.
- 285 Ryan Q, Headlee D, Acharya MR, Sparreboom A, Trepel J, Ye J, **Figg WD**, Hwang K, Chung E, Murgu A, Melillo G, Elsayed Y, Mongo M, Kalnitskiy M, Zwiebel J, Sausville EA. A Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase in Patients with Advanced Solid Tumor or Lymphoma. *J Clin Oncol* 2005;23:3912-22.

William Douglas Figg

Curriculum Vitae

Page 27 of 57

- 286 Kumar S, Raje N, Hideshima T, Ishitsuka K, Roccaro A, Shiraishi N, Hamasaki M, Yasui H, Munshi N, **Figg WD**, Anderson KC. Anti-myeloma Activity of Two Novel N-substituted and Tetrafluorinated Thalidomide Analogues. *Leukemia* 2005;19:1253-61.
- 287 Scripture CD, Szebeni J, Loos WJ, **Figg WD**, Sparreboom A. Comparative in vitro properties and Clinical Pharmacokinetics of Paclitaxel following the Administration of Taxol and Paxene. *Cancer Biol Therap* 2005;4:555-560.
- 288 Lakhani NJ, Lepper ER, Sparreboom A, Dahut WL, Venitz J, **Figg WD**. Determination of 2-methoxy-estradiol in Human Plasma, using Liquid Chromatography/Tandem-mass spectrometric Detection. *Rapid Commun Mass Spectrom* 2005;19:1176-82.
- 289 **Figg WD**, Retter A, Steinberg SM, Dahut WL. Inhibition of Angiogenesis: Thalidomide or Low Molecular Weight Heparin? *J Clin Oncol* (letter) 2005;23:2113-4.
- 290 Pingpank JF, Libutti SK, Chang R, Wood BJ, Neeman Z, Kam AW, **Figg WD**, Zhai S, Beresneva T, Steinberg SM, Seidel GD, Alexander HR. A Phase I Study of Hepatic Arterial Melphalan Infusion and Hepatic Venous Hemofiltration Using Percutaneously Placed Catheters in Patients with Unresectable Hepatic Malignancies. *J Clin Oncol* 2005;23:3465-74.
- 291 D'Amico AV, Chen MH, Cox MC, Dahut W, **Figg WD**. Prostate-Specific Antigen Response Duration Risk of Death for Patients with Hormone-Refractory Metastatic Prostate Cancer. *Urol* 2005;66:571-6.
- 292 Chau CH, **Figg WD**. Molecular and Phenotypic Heterogeneity of Hormone-Refractory Metastatic Prostate Cancer. *Cancer Biol Ther* 2005;4:166-7.
- 293 Sparreboom A, Loos WJ, Burger H, Sissung TM, Verweij J, **Figg WD**, Nooter K, Gelderblom H. Effect of ABCG2 421C>A Genotype on the Oral Bioavailability of Topotecan. *Cancer Bio Ther* 2005;4:650-8.
- 294 Lepper E, Baker SD, Parmenter M, Ries N, van Schaik RHN, Schenk PW, Price DK, Ahn D, Smith NF, Cusatis G, Ingersoll RG, Bates SE, Mathijssen RHJ, Verweij J, **Figg WD**, Sparreboom A. Effect of Common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the Cytochrome P4503A Phenotyping Probe Midazolam in Cancer Patients. *Clin Cancer Res* 2005;11:7398-7404.
- 295 Smith NF, Acharya MR, Desai N, **Figg WD**, Sparreboom A. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. *Cancer Biol Ther* 2005;4:815-8.
- 296 Acharya MR, Sparreboom A, Ventiz J, **Figg WD**. Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review. *Mol Pharmacol* 2005;68:917-32.
- 297 Sparreboom A, **Figg WD**. Recent Advances in Pharmacogenetic Approaches to Cancer Chemotherapy. *Inv New Drugs* 2005;23:511.
- 298 Best CJM, Gillespie JW, Perlmutter MA, Gathright Y, Gadisetti C, Duray PH, Gonzalez S, Velasco A, Linehan WM, Price D, **Figg WD**, Emmert-Buck MR, Chuaqui RF. Molecular Alterations in Primary Prostate Cancer Androgen Ablation Therapy. *Clin Cancer Res* 2005;11:6823-6834.
- 299 Smith NF, **Figg WD**, Sparreboom A. Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing Drug Elimination. *Exp Opinion Drug Metabol Toxicol* 2005;1:429-45.
- 300 Posadas EM, Gulley J, Arlen PM, Trout A, Parnes HL, Wright J, Steinberg SM, Lee MJ, Chung EJ, Trepel JB, Sparreboom A, Chen C, Jones E, **Figg WD**, Dahut WL. A Phase II Study of Oral Perifosine in Androgen Independent Prostate Cancer. *Cancer Biol Ther* 2005;4:1133-7.

- 301 Rozhansky F, Chen MH, Cox MC, Dahut W, **Figg WD**, D'Amico AV. PSA Velocity and Survival for Patients with Hormone Refractory Metastatic Prostate Carcinoma. *Cancer* 2005;106:63-67.
- 302 Scripture CD, **Figg WD**, Sparreboom A. The Role of Drug Metabolizing Enzymes in Clinical Responses to Chemotherapy. *Expert Opin Drug Metab Toxicol* 2005;2:17-25.
- 303 Chau CH, Permenter MG, Steinberg SM, Dahut WL, Price DK, **Figg WD**. Polymorphism of the hypoxia inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer. *Cancer Biol Ther* 2005;4:1222-5.
- 304 Scripture CD, Sparreboom A, **Figg WD**. Modulation of Cytochrome P450 Activity: Implications for Cancer Therapy. *Lancet Oncol* 2005;6:780-9.
- 305 Cox MC, Scripture CD, **Figg WD**. Leuprolide acetate given by a Subcutaneous Extended Release Injection: Less of a Pain? *Expert Rev Anticancer Ther*, 2005;5:605-11.
- 306 Tkacz V, Tohnya T, **Figg WD**. Cyclooxygenase-2 and Angiogenesis in Prostate Cancer. *Cancer Biol Ther* 2005;4:813-4.
- 307 Sharifi N, Dahut W, Steinberg SM, **Figg WD**, Tarassoff C, Arlen P, Gulley JL. A Retrospective Study of the Time to Clinical End Points for Advanced Prostate Cancer. *Br J Urol* 2005;96:985-9.
- 308 Luzzio FA, Duveau DY, Lepper E, **Figg WD**. Synthesis of Racemic 5-Hydroxy-3-Phthalimidoglutarimide. A Metabolite of Thalidomide Isolated from Human Plasma. *J Org Chem* 2005;70:10117-20.
- 309 **Figg WD**. Development of Thalidomide as an Angiogenesis Inhibitor for the Treatment of Androgen-Independent Prostate Cancer. *Clin Pharmacol Therap* 2006;79:1-8.
- 310 Acharya MR, Sparreboom A, Sausville EA, Conley B, Doroshow JH, Venitz J, **Figg WD**. Interspecies differences in protein binding of MS-275, a Novel Histone Deacetylase Inhibitor. *Cancer Chemother Pharmacol* 2006;57:275-81.
- 311 Chau CH, **Figg WD**. Whole or Partial Vessel Outgrowth Assays. In Staton CA, Lewis C, Bicknell R (Editors) Angiogenesis Assays: A Critical Appraisal of Current Techniques. Published by Wiley and Sons, New York, NY, 2006:105-121.
- 312 Smith N, Sparreboom A, **Figg WD**. Pharmacogenetics of irinotecan metabolism and transport: an update. *Toxicol In vitro* 2006;20:163-75.
- 313 Hwang K, Scripture CD, Gutierrez M, Kummar S, **Figg WD**, Sparreboom A. Determination of the Heat Shock Protein 90 Inhibitor 17-dimethylamino-ethylamino-17-demethoxygelanmycin (17-DMAG) in Plasma by Liquid Chromatography Electrospray Mass Spectrometry. *J Chromatogr B* 2006;830:35-40.
- 314 Acharya MR, Karp JE, Sausville EA, Hwang K, Ryan Q, Gojo I, Venitz J, **Figg WD**, Sparreboom A. Factors affecting the pharmacokinetics profile of MS-275, a Novel Histone Deacetylase Inhibitor, in Patients with Cancer. *Inv New Drugs*, 2006;24:367-75.
- 315 Singh AS, Macpherson GR, Ng S, Price DK, Schimmel D, **Figg WD**. Evaluation of Human Fetal Bone Implants in SCID mice as a Model of Prostate Cancer Bone Metastasis. *Oncol Report* 2006;15:519-24.

- 316 Dahut WL, Lakhani NJ, Gulley JL, Arlen PM, Kohn EC, Kotz H, McNally D, Parr A, Nguyen D, Yang X, Steinberg SM, Venitz J, Sparreboom A, **Figg WD**. Phase I Clinical Trial of Oral 2-methoxyestradiol (2ME2), an Antiangiogenesis and Apoptotic Agent, in Patients with Solid Tumors. *Cancer Biol Therap* 2006;5:22-7.
- 317 Travis LB, Rabkin CS, Brown LM, Allan JM, Alter BP, Ambrosone CB, Begg CB, Caporaso N, Chanock S, DeMichele A, **Figg WD**, Gospodarowicz MK, Greene MH, Hall EJ, Hisada M, Inskip P, Kleinerman R, Little JB, Malkin D, Ng AK, Offit K, Pui CH, Robinson LL, Rothman N, Shields PG, Strong L, Taniguchi T, Tucker MA, Wittes RE. Cancer Survivorship – Genetic Susceptibility and Second Primary Cancers: Research Strategies and Recommendations. *J Natl Cancer Inst* 2006;98:15-25.
- 318 Scripture CD, **Figg WD**, Sparreboom A. Peripheral Neuropathy Induced by Taxane Chemotherapeutics: Recent Insights. *Curr Neuropharmacol* 2006;4:165-72.
- 319 Cox MC, Dahut WL, **Figg WD**. The use of Thalidomide in Androgen-Independent Prostate Cancer. *J Urol Oncol* 2006;24:246-9.
- 320 Parnes H, **Figg WD**. Prostate Cancer Chemoprevention, *Pharmacotherapy* (letter) 2006;26:1533.
- 321 Lepper ER, Burger H, van Schaik RH, van Oosterom AT, de Bruijn EA, Guetens G, Prenen H, de Jong FA, Baker SD, Bates SE, **Figg WD**, Verweij J, Sparreboom A, Nooter K. Association of Enzymes and Transporter Genotypes with the Pharmacokinetics of Imatinib. *Clin Pharmacol Therap* 2006;80:192-201.
- 322 Sissung TM, Price DK, Sparreboom A, **Figg WD**. The Pharmacogenetics and Regulation of CYP1B1 – implications in hormone mediated tumor metabolism and a Novel Target for Therapeutic Intervention. *Mol Cancer Res* 2006;4:135-50.
- 323 **Figg WD**, Dunn L, Liewehr D, Thurman P, Steinberg S, Barrett JC, Birkinshaw J. Scientific Collaboration Results in Higher Citation Rates of Published Articles. *Pharmacotherapy* 2006;26:759-67.
- 324 De Marzo AM, Platz EA, Epstein JI, Ali T, Ballis A, Chan TY, Cheng L, Datta M, Egevad L, Ertoy-Baydar D, Farre X, Fine S, Iczkowski KA, Ittmann M, Knudsen BS, Loda M, Lopez-Beltran A, Magi-Galluzzi C, Mikuz G, Montironi R, Pikarsky E, Pizov G, Rubin MA, Samaratunga H, Sebo T, Sesterhenn IA, Shah R, Signoretti S, Simko J, Thomas G, Troncoso P, Tsuzuki T, van Leenders GJLH, Yang X, Zhou M, **Figg WD**, Hoque A, Lucia MS. A Working Group Classification of Focal Prostate Atrophy Lesions. *Am J Surg Path* 2006;30:1281-91.
- 325 Erratum: A Working Group Classification of Focal Prostate Atrophy Lesions. *Am J Surg Path* 2006;30:1489.
- 326 Lepper ER, Smith NF, Cox MC, Scripture CD, **Figg WD**. Thalidomide Metabolism and Hydrolysis: Mechanisms and Implications. *Current Drug Metabolism* 2006;7:677-85.
- 327 Scripture CD, **Figg WD**. Drug Interactions in Cancer Treatment. *Nature Rev Cancer* 2006;6:546-58.
- 328 Scripture C, **Figg WD**. Erratum. Drug Interactions in Cancer Therapy. *Nature Rev Cancer* 2006;6:741.
- 329 **Figg WD**, Cox MC, Alchalabi T, Dahut WL. Angiogenesis Inhibitors in Prostate Cancer. In Dawson N, Kelly WK (Editors) Prostate Cancer: Translational and Emerging Therapies. Published by Wiley-Liess Publications, New York, NY, 2006, pp127-143.

- 330 Warfel NA, Lepper E, Zhang C, **Figg WD**, Dennis P. Importance of the Stress Kinase p38 in Mediating the Direct Cytotoxic Effects of the Thalidomide Analogue, CPS49, in Cancer Cells and Endothelial Cells. *Clin Cancer Res* 2006;12:3502-9.
- 331 Sparreboom A, **Figg WD**. Identifying Sources of Interindividual Pharmacokinetic Variability with Population Modeling. *Clin Cancer Res* 2006;12:1951-3.
- 332 Ahlers CM, **Figg WD**. ETS-TMPRSS2 Fusion Gene Products in Prostate Cancer. *Cancer Biol Ther* 2006;5:254-5.
- 333 Ng SSW, Sparreboom A, Shaked Y, Lee C, Man S, Desai N, Soon-Shiong P, **Figg WD**, Kerbal RS. Influence of Formulation Vehicle on Metronomic Taxane Chemotherapy Albumin-bound versus Cremophor EL-based Paclitaxel. *Clin Cancer Res* 2006;12:4331-8.
- 334 Lakhani N, Sparreboom A, Venitz J, Dahut WL, **Figg WD**. Plasma Protein Binding of 2-methoxyestradiol. *Anticancer Drugs* 2006;17:977-83.
- 335 Gardner ER, Sparreboom A, Chu Z, **Figg WD**. Determination of Paclitaxel in Human Plasma by LC/MS/MS following the administration of Genaxol or Genetaxyl by Liquid Chromatography Tandem Mass Spectrometry. *Rapid Commun Mass Spectrom* 2006;20:2170-4.
- 336 Gulley J, Dahut W, **Figg WD**. Even More Cost Savings: Individualized Strategy for Dosing Leutinizing Hormone Releasing Hormone Agonists for Androgen-Independent Prostate Cancer. *J Oncol Practice* (letter) 2006;2:202.
- 337 Sion A, **Figg WD**. Lysyl Oxidase and Hypoxia – Induced Metastases. *Cancer Biol Ther* 2006;5:909-11.
- 338 Ge Y, Montano I, Freebern WJ, Haggerty CM, Ponciano-Jackson D, Chandramouli GVR, Lepper E, **Figg WD**, Jackson SH, Gardner K. Selective leukemic cell killing by a Novel Functional Class of Thalidomide Analogs. *Blood* 2006;108:4126-35.
- 339 Cox MC, Low JA, Lee JJ, Walshe JM, Denduluri N, Berman A, Permenter MG, Petros WP, Price DK, **Figg WD**, Sparreboom A, Swain SM. Influence of Garlic (*allium sativum*) on the Pharmacokinetics of Docetaxel. *Clin Cancer Res* 2006;12:4636-40.
- 340 Sissung TM, Mross K, Steinberg SM, **Figg WD**, Sparreboom A, Mielke S. Association of ABCB1 Genotypes with Paclitaxel-Mediated Peripheral Neuropathy and Neutropenia. *Eur J Cancer* 2006;42:2893-6.
- 341 Gardner ER, **Figg WD**, Sparreboom A. Pharmacogenomics of the Human ATP-Binding Cassette Transporter ABCG2. *Current Pharmacogenomics* 2006;4:331-44.
- 342 Tohnya TM, Ventiz J, Sparreboom A, **Figg WD**. Lenalidomide: Cancer Therapy via Antiangiogenesis and Immunomodulation. *Cur Cancer Therap Rev* 2006;2:223-9.
- 343 **Figg WD**, Chau CH. Heterogeneity in Drug Disposition Determines Interindividual Variability of Docetaxel Pharmacokinetics. *Cancer Biol Ther* 2006;5:840-1.
- 344 Sartor O, Alchalabi T, **Figg WD**. Assessing Progress Against Prostate Cancer. *Clin Genitourin Cancer* 2006;5:102-3.

- 345 Beverage JN, **Figg WD**. The Quantification of PSA mRNA Copies in Pathologically Normal Pelvic Lymph Nodes is a Viable Prognostic Indicator. *Cancer Biol Ther*, 2006;5:1094-5.
- 346 **Figg WD**, Ocker S. Prostate Cancer – 6th International Congress Review. *IDrug* 2006;9:675-8.
- 347 Smith E, Price DK, **Figg WD**. Piecing together the HIF-1 puzzle: the role of the CTGF as a molecular mechanism of HIF-1 regulation. *Cancer Biol Ther* 2006;5:1443-4.
- 348 Ahlers CM, **Figg WD**. Sifting Through the Multitude of Novel Therapies for Prostate Cancer. *Oncology* 2006;20:1792-6.
- 349 Schrupp DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, Hancox A, Hong JA, Chen GA, Pishchik V, **Figg WD**, Murgu AJ, Steinberg SM. Phase I Study of Decitabine-Mediated Gene Expression in Patients with Cancers Involving the Lungs, Esophagus, or Pleura. *Clin Cancer Res* 2006;12:5777-5785.
- 350 Luzzio FA, Duveau DY, **Figg WD**. A Chiral Pool Approach Toward the Synthesis of Thalidomide Metabolites. *Heterocycles* 2006;70:321-334.
- 351 Ocker S, Price DK, **Figg WD**. DNA Microarrays: Tissue Removal and Processing Affects Gene Expression. *Cancer Biol Ther* 2006;5:1608-9.
- 352 Smith NF, Marsh S, Scott-Horton TJ, Hamada A, Mielke S, Mross K, **Figg WD**, Verweij J, McLeod HL, Sparreboom A. Variants in the SLCO1B3 Gene: Interethnic Distribution and Association with Paclitaxel Pharmacokinetics. *Clin Pharmacol Therap* 2007;81:76-82.
- 353 Wu SL, Jones E, Gulley JL, Arlen PM, Chen CC, **Figg WD**, Dahut WL. Routine Interval Computed Tomography to Detect New Soft Tissue Disease Might Be Unnecessary in Patients with Androgen-Independent Prostate Cancer and Only to Bone Metastasis. *Br J Urol* 2007;99:525-8.
- 354 Deeken JF, **Figg WD**, Bates SE, Sparreboom A. Toward Individualized Treatment Prediction of Anticancer Drug Disposition and Toxicity with Pharmacogenetics. *Anticancer Drugs* 2007;18:111-26.
- 355 **Figg WD**, Folkman J (Editors). Angiogenesis: An Integrative Approach from Science to Medicine. Published by Springer Publishing, New York, NY, 2008;1-601.
- 356 Lakhani NJ, Sparreboom A, Xu X, Veenstra TD, Venitz J, Dahut WL, **Figg WD**. Characterization of in vitro and in vivo metabolic pathways of the Investigational Anticancer Agent, 2-methoxyestradiol. *J Pharmac Sci* 2007;96:1821-31.
- 357 Li H, Price DK, **Figg WD**. ADH1, an N-Cadherin Inhibitor, Evaluated in Preclinical Models of Angiogenesis and Androgen Independent Prostate Cancer. *Anticancer Drugs* 2007;18:563-8.
- 358 Gojo I, Jiemjit A, Trepel JB, Sparreboom A, **Figg WD**, Rollins S, Tidwell ML, Greer J, Chung EJ, Lee MJ, Gore SD, Sausville EA, Zwiebel J, Karp JE. Phase I and Pharmacological Study of MS275, A Histone Deacetylase Inhibitor, in Adults with Refractory and Relapsed Acute Leukemias. *Blood* 2007;109:2781-90.
- 359 DiLorenzo G, Autorino R, **Figg WD**, DePlacido S. Hormone Refractory Prostate Cancer: Where Are We Going? *Drugs* 2007;67:1109-24.

- 360 **Figg WD**, Li H, Sissung T, Retter A, Wu S, Gulley JL, Arlen P, Wright JJ, Parnes H, Fedenko K, Latham L, Steinberg SM, Jones E, Chen C, Dahut WL. Preclinical and Clinical Evaluation of Estramustine, Docetaxel and Thalidomide Combination in Androgen Independent Prostate Cancer. *Br J Urol* 2007;99:1047-55.
- 361 Beverage JN, Sissung TM, Sion AM, Danesi R, **Figg WD**. CYP2D6 Polymorphisms and the Impact on Tamoxifen Therapy. *J Pharm Sci* 2007;96:2224-31.
- 362 Chau C, **Figg WD**. Angiogenesis Therapy. In DeVita VT, Rosenberg SA (Editors) Cancer: Principles and Practice of Oncology 8th Edition. Published by Lippincott Williams and Wilkins, Philadelphia, PA 2008;527-36.
- 363 **Figg WD**, Chau C (Editors). Getting into Pharmacy School. Published by Kaplan Publishing, New York, NY, 2007.
- 364 Sissung TM, Gardner E, Gao R, **Figg WD**. Pharmacogenetics of Membrane Transporters: A Review of Current Approaches. *Methods Mol Biol* 2008;448:41-62.
- 365 Smith NF, Mani S, Schuetz EG, Yasuda K, Xi Z, Bates SE, **Figg WD**, Sparreboom A. Induction of Cytochrome P4503A4 by Vinblastine: Role of the Nuclear Receptor NR112. *Clinical Pharmacology Therapeut in press*.
- 366 Chau CH, Dahut WL, **Figg WD**. Development of Thalidomide and Its IMiD Derivatives (Chapter 34). In **Figg WD**, Folkman J (Editors). Angiogenesis: An Integrative Approach from Science to Medicine. Published by Springer, New York, NY, 2008;387-394.
- 367 Chau CH, **Figg WD**. Recent Advances in Angiogenesis Drug Development (Chapter 37). In **Figg WD**, Folkman J (Editors). Angiogenesis: An Integrative Approach from Science to Medicine. Published by Springer, New York, NY, 2008; 421-430.
- 368 Di Lorenzo G, Autorino R, Perdon S, Trusso F, De Laurentiis M, D'Armiento M, Gallo L, Mirone V, Altieri V, **Figg WD**, De Placido S. Docetaxel, Vinorelbine and Zoledronic Acid as First Line Treatment in Patients with Hormone Refractory Prostate Cancer: A Phase II Study. *Eur Urol* 2007;52:1020-7.
- 369 **Figg WD**. The Pharm.D. Investigator in Clinical Pharmacology: Supply and Demand. *Clinical Pharmacology Therapeut, in press*.
- 370 Alchalabi T, **Figg WD**. The Additive Effect of Thalidomide to Chemotherapy in Androgen Independent Prostate Cancer. *Cancer Biol Ther* 2007;6:318-9.
- 371 Aragon-Ching JB, Li H, Gardner ER, **Figg WD**. Thalidomide Analogues as Anticancer Drugs. *Recent Patents on Anti-Cancer Drug Discovery*, 2007;2:167-74.
- 372 Lal S, Wong ZW, Jada SR, Xiang X, Chen Shu X, Ang PC, **Figg WD**, Lee EJ, Chowbay B. Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian Breast Cancer Patients. *Pharmacogenomics* 2007;8:567-575.

- 373 Gills JJ, LoPiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, Borojerdi J, Warfel NA, Gardner ER, Danish M, Hollander MC, Kawabata S, Tsokos M, **Figg WD**, Steeg PS, Dennis PA. Nelfinavir, a lead HIV protease inhibitor, is a Broad Spectrum, Anticancer agent that induces Endoplasmic Reticulum Stress, Autophagy and Apoptosis in vitro and in vivo. *Clinical Cancer Res* 2007;13:5183-94.
- 374 Hamada A, Danesi R, Price DK, Sissung T, Chau C, Venzon D, Sparreboom A, Dahut WL, **Figg WD**. Association of a CYP17 polymorphism with Overall Survival in Caucasian Patients with Androgen Independent Prostate Cancer. *Urology* 2007;70:217-20.
- 375 Kummar S, Gutierrez M, Gardner ER, Hwang K, Chung EJ, Lee MJ, Maynard K, Kalnitskiy M, Donovan E, Chen A, Melillo G, Ryan QC, Conley B, Sausville E, Sparreboom A, **Figg WD**, Trepel JB, Zwiebel J, Doroshow JH, Murgu AJ. Phase I Trial of MS-275, a Histone Deacetylase Inhibitor Administered Weekly, in Refractory Solid Tumors and Lymphoid Malignancies. *Clin Cancer Res* 2007;13:5411-17.
- 376 Sharifi N, Dahut WL, **Figg WD**. Secondary Hormonal Therapy for Prostate Cancer: What Lies on the Horizon? *Br J Urology* 2008;101:271-4.
- 377 Sharif N, **Figg WD**. Androgen Receptor Modulation: Lessons Learned from Beyond the Prostate. *Cancer Bio Therap* 2007;6:1358-9.
- 378 Chen X, Gardner ER, Gutierrez M, Kummar S, **Figg WD**. Determination of 17-dimethylaminoethylamino-17-demethoxygeldanamycin in human plasma by liquid chromatography with mass-spectrometric detection. *J Chromatogr B* 2007;858:302-6.
- 379 Li H, Raia V, Bertolini F, Price DK, **Figg WD**. Circulating Endothelial Cells as a Therapeutic Marker for Thalidomide in Combination Therapy with Chemotherapy Drugs in a Human Prostate Cancer Model. *Br J Urol* 2008;101:884-8.
- 380 Sharifi N, **Figg WD**, Dahut WL. Novel Agents for Prostate Cancer (Chapter 17). In Gulley JL, Dahut WL, Moul JW, Sandler HM (Editors) *Prostate Cancer: A Clinical Guide*. Published by Lippincott, Williams and Wilkins, Philadelphia, PA 2008;167-73.
- 381 Sissung TM, Danesi R, Price DK, Steinberg SM, de Wit R, Zahid M, Gaikwad N, Cavalieri E, Dahut WL, Sackett DL, **Figg WD**, Sparreboom A. Association of the CYP1B1*3 allele with Survival in Patients with Prostate Cancer Receiving Docetaxel. *Mol Cancer Therap* 2008;7:19-26.
- 382 Chu Z, Chen JS, Liao CT, Wang HM, Lin YC, Yang MH, Chen PM, Gardner ER, **Figg WD**, Sparreboom A. Oral Bioavailability of a Novel Paclitaxel Formulation (Genetaxyl) Administered with Cyclosporin A in Cancer Patients. *Anticancer Drugs* 2008;19:275-81.
- 383 Fine HA, Kim L, Albert PS, Duic JP, Ma H, Zhang W, Tohnya T, **Figg WD**, Royce C. A phase I trial of Lenalidomide in patients with Recurrent Primary Central Nervous System Tumors. *Clinical Cancer Res* 2007;13:7101-6.
- 384 Chen X, Gardner ER, Price DK, **Figg WD**. Development and Validation of an LC-MS Assay for Finasteride and its Application to Prostate Cancer Prevention Trial Sample Analysis. *J Chromatogr Sc* 2008;46:356-61.

- 385 Dahut WL, Scripture C, Posadas E, Jain L, Gulley JL, Arlen PM, Wright JJ, Yu Y, Cao L, Steinberg SM, Aragon-Ching JB, Venitz J, Jones E, Chen CC, **Figg WD**. A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer. *Clin Cancer Res* 2008;14:209-14.
- 386 **Figg WD**, Chau C, Small E (Editors). Drug Management of Prostate Cancer. Published by Humana Publishing, Totowa, NJ, 2007, [in press](#).
- 387 Aragon-Ching JB, Gillespie J, Price DK, Chuaqui R, Rodriquez-Canales J, Steinberg SM, Dahut WL, **Figg WD**. Lack of Prognostic Significance of Prostate Biopsies in Metastatic Androgen Independent Prostate Cancer. *Br J Urology*, 2007;100:1245-8.
- 388 Schrupp DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, Hancox A, Hong JA, Chen GA., Kruchin E, Wright JJ, Rosing DR, Sparreboom A, **Figg WD**, Steinberg SM. Clinical and Molecular Response in Lung Cancer Patients Receiving Romidepsin. *Clin Cancer Res* 2008;14:188-98
- 389 Jain L, Gardner ER, Venitz J, Dahut W, **Figg WD**. Development of a Rapid and Sensitive LC-MS/MS Assay for the Determination of Sorafenib in Human Plasma. *J Pharm Biomed Anal* 2008;46:362-7.
- 390 Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Heller G, Basch E, Kelly WK, **Figg WD**, Small EJ, Beer TM, Wilding G, Martin A, Hussain M. Design and Endpoints of Clinical Trials for Patients with Progressive Prostate Cancer and Castrate Levels of Testosterone. *J Clin Oncol* 2008;26:1148-59.
- 391 Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Heller G, Basch E, Kelly WK, **Figg WD**, Small EJ, Beer TM, Wilding G, Martin A, Hussain M. Author Reply: Design and Endpoints of Clinical Trials for Patients with Progressive Prostate Cancer and Castrate Levels of Testosterone. *J Clin Oncol*, (Letter) [In press](#).
- 392 Hamada A, Sissung T, Price DK, Danesi R, Venzon D, Maeda K, Sparreboom A, Mitsuya H, Dahut WL, **Figg WD**. Effect of *SLCO1B3* haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer. *Clin Cancer Res* 2008;14:3312-8.
- 393 Hoque A, Goodman P, Ambrosone CB, **Figg WD**, Price DK, Kopp W, Wu X, Conroy J, Lehman TA, Santella RM. Extraction of DNA from Serum for High-Throughput Genotyping: Findings from Pilot Studies within the Prostate Cancer Prevention Trial. *Urol*, [In press](#).
- 394 Gardner ER, Sparreboom A, Verweij J, **Figg WD**. Lack of ABC Transporter Autoinduction in Mice Following long-term Exposure to Imatinib. *Cancer Bio Ther*. [In press](#).
- 395 Ge Y, Byun JS, De Luca P, Gueron G, Yabe I, Sadiq-Ali SG, **Figg WD**, Quintero J, Haggerty CM, Li QQ, DeSiervi A, Gardner K. Combinatorial Anti-leukemic disruption of Oxidative Homeostasis and Mitochondrial Stability by the Redox Reactive Thalidomide CPS49 and Flavopiridol. *Mol Pharmacol*. [In press](#).
- 396 Di Lorezo G, **Figg WD**, Fossa SD, Mirone V, Autorino R, Longo N, Imbimbo C, Perdona S, Giordano A, Giuliano M, Labianca R, De Placido S. Combination of Bevacizumab and Docetaxel Pretreated Hormone Refractory Prostate Cancer: A Phase II Study. *Eur Urol*, [in press](#).
- 397 Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching J, Hawkins M, Sparreboom A, **Figg WD**. Randomized, Crossover Pharmacokinetic Study of Paclitaxel and ABI-007 in Patients with Advanced Solid Tumors. *Clin Cancer Res*, [in press](#).

- 398 Sissung TM, Baum C, Deeken J, Price DK, Dahut W, Sparreboom A, **Figg WD**. ABCB1 genetic variation Influences the Toxicity and Clinical Outcome of Patients Treated with Docetaxel. *Clin Cancer Res*. [In press](#).
- 399 Arlen PM, Bianco F, Dahut WL, D'Amico A, **Figg WD**, Freedland SJ, Gulley JL, Kantoff PW, Kattan MW, Lee A, Regan MM, Sartor O. Prostate-Specific Antigen Working Group Guidelines on Prostate Specific Antigen Doubling Time. *J Urol* 2008;179:2181-5.
- 400 Arlen PM, Bianco F, Dahut WL, D'Amico A, **Figg WD**, Freedland SJ, Gulley JL, Kantoff PW, Kattan MW, Lee A, Regan MM, Sartor O. Author Reply - Prostate-Specific Antigen Working Group Guidelines on Prostate Specific Antigen Doubling Time. *J Urol* 2008;179:2185-6.
- 401 Gao R, Price DK, Sissung T, Reed E, **Figg WD**. Ethnic Disparities in Americans of European Descent versus Americans of African Descent related to Polymorphic ERCC1, ERCC2, XRCC1 and PARP1. *Mol Cancer Therap* 2008;7:1246-50.
- 402 Gardner ER, Dahut WL, **Figg WD**. Quantitative Determination of Total and unbound Paclitaxel in Human Plasma following Abraxane Treatment. *J Chrom B* 2008;862:213-8.
- 403 **Figg WD**, Chau CH, Okita R, Preusch P, Tracy TS, McLeod H, Reed M, Pieper J, Knoell D, Miller K, Speedie M, Blouin R, Kroboth P, Koda-Kimble MA, Taylor P, Cohen J, Giacomini K. Pharm.D. Pathways to Biomedical Research: The National Institutes of Health Pharmacy Research Conference. *Pharmacotherapy*, [in press](#).
- 404 Sharifi N, Hamada A, Sissung T, Danasi R, Venzon D, Gulley JL, Price DK, Dahut W, **Figg WD**. A Polymorphism in the OATP1B1 Transporter of Testosterone is a Determinant of Androgen Independence in Prostate Cancer. *Br J Urol*, [in press](#).
- 405 Chen X, Gardner ER, **Figg WD**. Determination of the cyclic depsipeptide FK228 in human and mouse plasma by liquid chromatography with mass-spectrometric detection. *J Chrom B* 2008;865:153-8.
- 406 Gardner E, Dahut W, **Figg WD**. Thalidomide and Thalidomide Analogs. In **Figg WD**, Chau C, Small E (Editors). Drug Management of Prostate Cancer. Published by Humana Publishing, Totowa, NJ, 2007, [in press](#).
- 407 Sissung T, **Figg WD**. Clinical Pharmacology and Pharmacogenetics in Prostate Cancer. In **Figg WD**, Chau C, Small E (Editors). Drug Management of Prostate Cancer. Published by Humana Publishing, Totowa, NJ, 2007, [in press](#).
- 408 Danish M, Sissung T, Price DK, **Figg WD**. Genetic Stability of Tumor Microenvironment. *Cancer Bio Ther*, [in press](#).
- 409 Smith NF, Baker SD, **Figg WD**, Sparreboom A. Modulation of Erlotinib Pharmacokinetics in Mice by a Novel Cytochrome P450 3A4 Inhibitor, BAS100. *Br J Cancer* 2008;98:1630-2.
- 410 Sharif N, Dahut WL, **Figg WD**. The Genetics of Castrate-Resistant Prostate Cancer: What Can The Germline Tell Us? *Clin Cancer Res*, [in press](#).
- 411 Gulley JL, Aragon-Ching JB, Steinberg SM, Hussain MH, Sartor O, Higano C, Petrylak D, Chatta GS, Arlen PM, **Figg WD**, Dahut WL. Kinetics of Serum Androgen Normalization after Limited Androgen Deprivation Therapy in Non-Metastatic Prostate Cancer. *J Urol*, [in press](#).

William Douglas Figg

Curriculum Vitae

Page 36 of 57

- 412 Aragon-Ching JB, Ning YM, Chen CC, Latham L, Guadagnini JP, Gulley JL, Arlen PM, Wright JJ, Parnes H, **Figg WD**, Dahut WD. Osteonecrosis of the jaw (ONJ) in Castrate-Resistant Prostate Cancer (CRPC) Patients Receiving ATTP (Bevacizumab, Docetaxel, Thalidomide, and Prednisone). *Cancer Invest*, [in press](#).
- 413 Gardner E, Ahlers C, Shukla S, Sissung T, Ockers S, Price DK, Hamada A, Robey R, Steinberg S, Ambudkar S, Dahut WL, **Figg WD**. Association of ABCG2 C421A Polymorphism with Prostate Cancer Risk and Survival. [In press](#).
- 414 Chau CH, McLeod HL, **Figg WD**. Validation of Analytical Methods for Biomarkers Employed in Clinical Trials. *Clin Cancer Res*. [In press](#).
- 415 Chau C, **Figg WD**. Angiogenesis in Prostate Cancer. In **Figg WD**, Chau C, Small E (Editors). Drug Management of Prostate Cancer. Published by Humana Publishing, Totowa, NJ, 2007. [In press](#).
- 416 Chau C, **Figg WD**. Preclinical Models. In Kelly WK, Halabi S (Editors). Fundamentals of Oncology Clinical Trials. [In press](#).
- 417 Wang W, **Figg WD**. Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance, *Cancer Bio Ther*. [In press](#).

Submitted

- 418 Ge Y, L QQ, Yabe I, **Figg WD**, Quintero J, Haggerty CM, Gardner K. Functional Transcriptional Pathways and Biomarker Profiling of Novel Selective cytokine Inhibitory Drugs in Mitogen-Activated Leukemic Cells.
- 419 Sissung TM, Pekarz RL, Steinberg SM, Bates SE, Price DK, Hwang K, **Figg WD**, Sparreboom A. ABCB1 variants and QTc interval Prolongation Associated with the Cyclic Depsipeptide FK228.
- 420 Chau CH, Steinberg SM, Price DK, **Figg WD**. Identification of SUMO-4 polymorphism in cancer cell lines and prostate cancer.
- 421 Chau CH, Permenter MG, Price DK, **Figg WD**. Detection of HIF-1alpha polymorphisms in the NCI60 cell panel.
- 422 **Figg WD**, Cox MC, Thurman PW. Differences Between Business Leader and Healthcare Professional Reliance on Academic Research.
- 423 Monga M, Headlee D, Messman R, Elsayed Y, Murgo A, Melillo G, Woo W, Zhai S, Hwang K, **Figg WD**, Senderowicz A, Hollingshead M. Arbutin SG, Sausville EA. A Phase I Trial of Oral Perifosine with Different Loading Schedules in Patients with Refractory Neoplasms.
- 424 Marti GE, Stetler-Stevenson MA, Drbohlav N, White T, Staudt L, **Figg WD**, Tohnya T, Jaffe E, Dunleavy KM, Janik J, Wilson WH. Phase I Trial of 7-Hydroxystaurosporine (UCN-01) and Fludarabine Phosphate (FAMP) In Vivo Evidence of UCN-01 Induced Apoptosis in CLL.
- 425 Therapontos C, Erskine L, Gardner E, Li H, **Figg WD**, Vargesson N. Thalidomide induces limb-specific defects by targeting vascular smooth muscle cell deficient blood vessels.
- 426 Mucci LA, Stark JR, Ma J, Li H, Stampfer MJ, Gaziano M, Kantoff PW, Hennessey K, **Figg WD**, Abe M. Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A Prospective Study.

William Douglas Figg

Curriculum Vitae

Page 37 of 57

- 427 Stein WD, **Figg WD**, Dahut WL, Stein AD, Hoshen MB, Price DK, Bates SE, Fojo T. Tumor Growth Rates Derived from Data for Patients on a Clinical Trial Correlate Strongly with Patient Survival. A Novel Strategy for Evaluation of Clinical Trial Data.
- 428 Gardner ER, Smith NF, **Figg WD**, Sparreboom A. Influence of the Dual ABCB1 and ABCG2 Inhibitor Tariquidar on the Disposition of Oral Imatinib in Mice.
- 429 Deeken J, Cormier T, Price DK, Steinberg SM, Tran K, Liewehr DJ, Hardenbol P, Dahut WL, Miao X, **Figg WD**. A Pharmacogenetic Study of Docetaxel and Thalidomide in Patients with Androgen-Independent Prostate Cancer Using the New Affymetrix DME-T 1.0 Genotyping Platform.
- 430 Flowers L, Wick J, **Figg WD**, McClelland RH, Shiber M, Britton JE, Ngo DK, Borders-Hemphill V, Zee J. U.S. Public Health Service Commissioned Corps Pharmacists: Making a Difference in Advancing the Nation's Health.
- 431 Clamp DA, Yu JJ, Gao R, Jett J, Zot H, Clump AG, Shockey M, Gannett P, Coad JE, **Figg WD**, Reed E, Flynn DC. A Single Nucleotide Polymorphism in AFAP-110 Enables it to Efficiently Activate cSrc.
- 432 Azad NS, Aragon-Ching JB, Dahut WL, Posades EM, Gutierrez M, **Figg WD**, Steinberg SM, Turner ML, Kohn EC, Kong HH. A Comparison of Dermatologic Toxicities Single Versus Combination Agent Anti-VEGF Therapy.
- 433 Dahut WL, Tohnya TM, Aragon-Ching JB, Woo S, Gulley JL, Arlen PM, Venitz J, Wright JJ, **Figg WD**. A Phase I Study of Oral CC-5013 (Lenalinomide, Revlimid) in Patients with Refractory Metastatic Cancer.
- 434 **Figg WD**, Steinberg SM, Gulley JL, Arlen PM, Aragon-Ching JB, Sartor O, Petrylak DP, Higano CS, Hussain MH, Dahut WL. A Double Blind Randomized Crossover Study of Oral Thalidomide versus Placebo in Patients with Stage DO Androgen Dependent Prostate Cancer Following Limited Hormonal Ablation.
- 435 Chau CH, **Figg WD**. The Role of Peroxisome Proliferation-activated Receptors in Prostate Cancer.
- 436 Sung SY, Hsieh CL, Law A, Zhou H, Pathak S, Multani AS, Lim S, Coleman IM, Wu LC, **Figg WD**, Dahut WL, Nelson P, Lee JK, Amin MB, Johnstone PA, Marshall FF, Chung LWK. Permanent cytogenetic and Gene Expression Changes in Cancer-Associated Stromal Cells under 3-D co-culture that Promote Prostate Cancer Growth and Progression.
- 437 Woo S, Gardner ER, Chen XH, Ockers SB, Baum CE, Sissung TM, Price DK, Frye R, Peikarz RL, Bates SE, **Figg WD**. Population Pharmacokinetics of Cyclic Romidepsin in Patients with Cutaneous T-cell Lymphoma and Relapsed Peripheral T-cell Lymphoma.
- 438 Peikarz RL, Frye R, Turner M, Wright JJ, Allen S, Kirschbaum MH, Zain J, Prince M, Leonard J, Geskin L, Hutchins L, Craig M, Reeder C, **Figg WD**, Gardner ER, Chen X, Liewehr D, Steinberg S, Jaffe E, Stetler-Stevenson MA, Fojo AT, Bates SE. A Multi-Institutional Phase II Trial of HDAC Inhibitor Romidepsin as Monotherapy for Patients with Cutaneous T-cell Lymphoma.

Over 350 Abstracts

Invited Presentations:

- 1 "The Pharmacokinetics of Immunotoxins" Georgetown University, School of Medicine, Washington, DC, December 1994.
- 2 "Utilization of Pharmacokinetic Principles in Anticancer Drug Development" Louisiana State University Medical Center, Shreveport, LA, June 1995.
- 3 "The Mutated Androgen Receptor and Its Role in the Development of Hormone Refractory Prostate Cancer" Uniformed Services University of Health Sciences, Medical School, Bethesda, MD, January 1996.
- 4 "Role of Pharmacist in Government Research (i.e., NIH)" Albany College of Pharmacy, Albany, NY, February 1996.
- 5 "Suramin in Prostate Cancer: The NCI's Experience" University of Indiana's 7th Annual Uro-Onc Meeting, New Orleans, LA, November 1996.
- 6 "Update on the Treatment of Stage D Prostate Cancer," University of Arkansas Cancer Center, Little Rock, AR, January 1997.
- 7 "Preclinical Screening of Angiogenesis Inhibitors," 1st Annual Invitational Oncology Pharmacy Conference, Newport Beach, CA, February 1997.
- 8 "Thalidomide in the Treatment of Prostate Cancer," Johns Hopkins Oncology Center, Baltimore, MD, March 1997.
- 9 "Inhibition of Angiogenesis," CaPCURE Annual Meeting, Tahoe, NV, September 1997.
- 10 "Phase II of Thalidomide in Androgen Independent Prostate Cancer," 4th Annual Angiogenesis Meeting, Hamilton, Bermuda, October 1997.
- 11 "Dilemmas in the Development of New Agents to Treat Hormone Refractory Prostate Cancer," Harvard Medical School, Boston, MA, February 1998.
- 12 "PSA as a Surrogate Marker In Metastatic Prostate Cancer," 2nd Annual Invitational Oncology Pharmacy Conference, Newport Beach, CA, February 1998.
- 13 "The Role of Angiogenesis Inhibitors in Prostate Cancer," Strategic Research Institute, Princeton, NJ, March 1998.
- 14 "Treatment of Stage D0 Prostate Cancer with Angiogenesis Inhibitors," Aberdeen University Medical School, Aberdeen, Scotland, June 1998.
- 15 "Validation of a Rat Aorta Angiogenesis Model," Nagoya Cancer Meeting, Nagoya, Japan, September 1998.
- 16 "Tumor Markers as Surrogate Endpoints," American Association of Pharmaceutical Scientist, San Francisco, CA, November 1998.
- 17 "Clinical Development of Matrix Metalloproteinase Inhibitors," 1st International Symposium on Anti-Angiogenic Agents, Dallas, Texas, January 1999.
- 18 "Clonal Analysis of Trinucleotide Repeat in Androgen Receptor," 3rd Annual Invitational Oncology Pharmacy Meeting, Napa Valley, California, February 1999.

William Douglas Figg
Curriculum Vitae
Page 39 of 57

- 19 "Surrogate Endpoints of Antiangiogenesis Clinical Trials," Institute for International Research, Bethesda, MD, February 1999.
- 20 "Trinucleotide Repeat in the Androgen Receptor," South West Oncology Group, Chicago, IL, July 1999.
- 21 "Anticancer Drug Development Targeted towards Solid Tumors," Breast Cancer Think Tank, Chantilly, VA, July 1999.
- 22 "Thalidomide in Solid Tumors," NCI Molecular and Clinical Grand Rounds, Bethesda, MD, September 1999.
- 23 "Men's Health - Treatment of Prostate Cancer," University of Wisconsin Symposium, Milwaukee, WI, September 1999.
- 24 "Advances in the Treatment of Androgen Independent Prostate Cancer," American College of Clinical Pharmacy, Kansas City, MO, October 1999.
- 25 "Thalidomide in Metastatic Prostate Cancer," Mt Sinai Cancer Center, New York, NY, November 1999.
- 26 "Importance of Apoptosis in the Development and Treatment of Cancer," American Society of Hospital System Pharmacist, Orlando, FL, December 1999.
- 27 "Angiogenesis as an Anticancer Target" National Institutes of Health Clinical Center Grand Rounds, Bethesda, MD, December 1999.
- 28 "Treatment Options for Metastatic Prostate Cancer," Cornell University Medical Center - New York Hospital Hematology/Oncology Grand Rounds, New York, NY, January 2000.
- 29 "Species Specificity for Endostatin," University of Wisconsin Cancer Center/School of Pharmacy Grand Rounds, Madison, WI, January 2000.
- 30 "Moving MMP Inhibitors from Bench to Clinic," Invasion Metastasis Conference Japan/USA, Maui, HI, February 2000.
- 31 "Development Plan for Cytostatic Anticancer Agents," Cell Biology Department Seminar Series, MD Anderson Cancer Center Grand Rounds, Houston, TX, February 2000.
- 32 "AIPC - What Treatments are Available," Medical College of Virginia, Richmond, VA, February 2000.
- 33 "Combination Therapy (Angiogenesis Inhibition, MMP Inhibition, and Chemotherapy) for the Treatment of Prostate Cancer," Cancer Center Grand Rounds, Albert Einstein Medical School, New York, NY, March 2000.
- 34 "Treatment Options for Metastatic Prostate Cancer," Seminars in Oncology, Howard University Medical School, Washington, DC, April 2000.
- 35 "Clinical Pharmacology for Angiogenesis Inhibitors - Abstract Highlights" American Society of Clinical Oncology Annual Meeting, New Orleans, LA, April 2000.
- 36 "Identification of Analogs of Thalidomide that Inhibit Angiogenesis" VA Hospital University of Pittsburgh, Pittsburgh, PA, August 2000.
- 37 "Bioassay for Angiogenesis" North Shore University Medical Hospital, Manhasset, NY, September 2000.

- 38 "Metabolism of Thalidomide" Multiple Myeloma Foundation Round Table, Boston, MA, October 2000.
- 39 "Treatment of Metastatic Prostate" Novel Molecular Targets in the Treatment of Cancer, Buenos Aires, Argentina, October 2000.
- 40 "Targeting Invasion and Metastasis in the Treatment of Cancer" Novel Molecular Targets in the Treatment of Cancer, Buenos Aires, Argentina, October 2000.
- 41 "Targeting Angiogenesis in the Treatment of Cancer" NIH Research Festival, Bethesda, MD, October 2000.
- 42 "Advances in the Treatment of Prostate Cancer" University of California at Los Angeles Cancer Center, LA, Calif., November 2000.
- 43 "Finding a Role for Angiogenesis Inhibitors in the Treatment of Prostate Cancer" Cancer Chemotherapy Foundation, Mt Sinai, NY, November 2000.
- 44 "Advances in the Treatment of Androgen Independent Prostate Cancer" VA Hospital Kansas City, MO, November 2000.
- 45 "Thalidomide: Place in Solid Tumor Therapy" University of Kansas, Kansas City, MO, November 2000.
- 46 "Screening for Angiogenesis Inhibitors" Washington Hospital Center Cancer Center, Washington, DC, January 2001.
- 47 "Novel Inhibitors of Angiogenesis" 1st International Congress on Prostate Cancer, San Juan, PR, June 2001.
- 48 "Isozymes Responsible for the Metabolism of Thalidomide" International Congress of Therapeutic Drug Monitoring, Washington, DC, September 2001.
- 49 "Developing Analogs of Thalidomide" Los Angeles VA Hospital, Los Angeles, CA, October 2001.
- 50 "Stage D0 Cooperative Trial for Prostate Cancer" Seattle Urology Association, Seattle, WA, November 2001.
- 51 "Finding a Clinical Role for Antiangiogenic Therapy" Fred Hutchinson Cancer Research Center, Seattle, WA, November 2001.
- 52 "Prostate Cancer: Treatment Options" West Virginia University School of Pharmacy, Morgantown, WV, February 2002.
- 53 "How to Form a Drug Development Program" West Virginia University Cancer Center, Morgantown, WV, February 2002.
- 54 "Evaluation of Endostatin in Human Saphenous Vein Model" Cold Spring Harbor, NY, March 2002.
- 55 "The Role of Circulating Endothelial Cells in Angiogenesis of a Solid Tumor" North Dakota State University, Fargo, ND, March 2002.
- 56 "Preclinical Models to Assess Angiogenesis" International Conference on Prostate Cancer, Barcelona, Spain, April 2002.
- 57 "New Agents Targeting Prostate Cancer" International Conference on Prostate Cancer, Barcelona, Spain, April 2002.

- 58 "Identification of Novel Agents to Inhibit Angiogenesis" NIH Clinical Center Grand Rounds, Bethesda, Maryland, June 2002.
- 59 "Angiogenesis Inhibitors in the Treatment of GU Cancers: Real or Fiction" 2nd Annual GU Malignancy International Conference, St. Thomas, USVI, July 2002.
- 60 "The Business of Science: The Relationship between the Private Sector and the Public Sector" Columbia University School of Business, New York, NY, July 2002.
- 61 "Pharmacogenetic variance in the Cytochrome P4502C19 Isozyme in patients with Prostate Cancer" Schelling Conference, American Cancer Society, Santa Cruz, CA, September 2002.
- 62 "Herbal Therapies for Patients with Prostate Cancer" Alliance for the Prevention and Treatment of Prostate Cancer, Morristown, New Jersey, October 2002.
- 63 "Preclinical Models to Screen for Antiangiogenic Agents" Society of Biological Therapy, San Diego, CA, November 2002.
- 64 "Docetaxel plus Thalidomide compared with Docetaxel in patients with AIPC" Chemotherapy Foundation, New York, NY., November 2002.
- 65 "Combining Agents that Target Endothelial Cells with Cytotoxic Chemotherapy" LSU CE Program, New Orleans, LA, November 2002.
- 66 "Randomized Phase II Trial of Docetaxel plus Thalidomide vs docetaxel in Patients with AIPC" 2nd International Summit of Opinion Leaders in GU Malignancy, St. Thomas USVI, January 2003.
- 67 "The Future of Angiogenesis Inhibition in the Treatment of Cancer" Baylor Medical School, Houston, TX, March 2003.
- 68 "Molecular Targeted Therapy for the Treatment of Cancer – Drug Development Road Map" West Virginia University Medical School Grand Rounds, Morgantown, WV, March 2003.
- 69 "The Role of Taxotere in the Treatment of Metastatic Prostate Cancer" Roundtable on GU Oncologist, Palm Beach, FL, March 2003.
- 70 "Tumor Angiogenesis" NIH Pharmacy Department 8th Annual CE Program, Bethesda, MD, May 2003.
- 71 "Drug Development for Targeted Anticancer Agents" University of New Mexico, Albuquerque, NM, June 2003.
- 72 "Thalidomide Plus Taxotere" ASCO Aventis Investigators Meeting, Chicago, IL, June 2003.
- 73 "Where do we go with agents that target endothelial cells as a Anticancer Therapy" Instituto Nacional de Cancer, Rio De Janeiro, Brazil, June 2003.
- 74 "Thalidomide and the Treatment of Kidney Cancer" Kidney Cancer Association, Chicago, IL, July 2003.
- 75 "Determining the Starting Dose for Phase 1 Trials" CBI's Conference on Maximizing Phase 1 Studies, Alexandria, VA, September 2003.
- 76 "Genetic Variables in Androgen Metabolism" NCI's Hormones in Cancer Conference, Hunt Valley, MD, October 2003.

- 77 “Angiogenesis Inhibitors in Prostate Cancer” American Urological Association Section Meeting, Boca Raton, FL, October 2003.
- 78 “Biomarkers in Cancer Trials” Institute for International Research, Phase I Trials in Oncology, Washington, DC January 2004.
- 79 “Thalidomide Analogs in Renal Cancer” 3rd Annual Meeting on GU Cancers, Santa Barbara, CA February 2004.
- 80 “Microarray Analysis of Androgen Dependent and Androgen Independent Prostate Cancer” Androgen Metabolism Symposium, Keystone, CO March 2004.
- 81 “Combining Angiogenesis Inhibitors with Chemotherapy in the Treatment of Pancreatic Cancer” Pisa, Italy April 2004.
- 82 “Antiangiogenesis Agents in the Treatment of Renal Cell Cancer” ASCO Annual Meeting, New Orleans, LA June 2004.
- 83 “Treatment Options for Metastatic GU Cancer” University of Iowa GU Conference, Iowa City, IA June 2004.
- 84 “Update on Angiogenesis Inhibitors in GU Cancer” 4th Annual International Prostate Cancer Congress, Freeport, Bahamas, July 2004.
- 85 “How are Pharmaceuticals Developed and Approved in the US” Columbia University’s School of Public Health, August 2004.
- 86 “Pharmacogenetics of Prostate Cancer” Italian Society of Pharmacology, University of Pisa, Pisa, Italy, October 2004.
- 87 “Developing Anticancer Agents (Lead Compound to IND)” University of Delaware, Newark, DE, November 2004.
- 88 “Interactions between Anticancer Agents and Herbal Products” NCAM, Bethesda, MD, December 2004.
- 89 “Survival Update for the Combination of Thalidomide and Docetaxel in AIPC” ASCO Prostate Cancer Meeting, Orlando, FL, February 2005.
- 90 “Leon Goldberg Lecture – Relationship between Anticancer Drug Development and Pharmacogenetics” American Society of Clinical Pharmacology and Therapeutics, Orlando, FL, March 2005.
- 91 “Angiogenesis as a Target for Prostate Cancer Drug Development” University of Michigan Department of Urology, Ann Arbor, MI, March 2005.
- 92 “NCI’s Direction in the Treatment of AIPC” National Complementary and Alternative Medicine Institute, Bethesda, MD, March 2005.
- 93 “Using Preclinical Models to Influence Anticancer Drug Development” Pharmaceutical Summit, Philadelphia, PA, March 2005.
- 94 “Using Preclinical Pharmacogenetics Information to Influence Clinical Development of Anticancer Agents” American College of Clinical Pharmacology, Myrtle Beach, SC, April 2005.

William Douglas Figg

Curriculum Vitae

Page 43 of 57

- 95 “Pharmacogenetics Influence in Healthcare Management” Delaware Valley Healthcare Association, Philadelphia, PA, April 2005.
- 96 “Combination of Thalidomide and Docetaxel in AIPC” Society of Urologic Oncology, San Antonio, TX, May 2005.
- 97 “Advances in the Treatment of Androgen Independent Prostate Cancer” COA Annual Meeting of the Public Health Service. Philadelphia, PA, June 2005.
- 98 “Translating Research into Healthcare Outcomes” Asian Society of Pharmacy, Singapore, June 2005.
- 99 “Pharmacogenetics of Anticancer Drug Development” Asian Society of Pharmacy, Singapore, June 2005.
- 100 “Thalidomide in the Treatment of AIPC” National Cancer Center, Singapore, June 2005.
- 101 “Pharmaceutical Industry’s Strategy in Developing New Agents” Columbia University’s Public Health School, New York, NY, July 2005.
- 102 “ABCG2 – Polymorphisms in this Transporter can Alter the Pharmacokinetics of Drugs” FASEB Saxon River, VT, July 2005.
- 103 “Endothelial Cells in Solid Tumors” Washington Hospital Center, Washington, DC, September 2005.
- 104 “Research Pharmacist’s Role in Anticancer Drug Development” University of Southern California School of Pharmacy, Los Angeles, CA, October 2005.
- 105 “Synergy between Chemotherapy and Targeted Anticancer Agents” Molecular Oncology Conference, Crete, Greece, October 2005.
- 106 “The Relationship between Inflammation and Prostate Cancer” American College of Clinical Pharmacy, San Francisco, CA, October 2005.
- 107 “Research within the Intramural Program at the National Institutes of Health” University of California San Francisco, CA, October 2005.
- 108 “The importance of genetic Variances in Response to Anticancer Treatments” Health Disparity Conference, National Institutes of Health, November 2005.
- 109 “The Future of Pharmacy” University of Sydney, Sydney, Australia, November 2005.
- 110 “Rational Drug Design and Development” University of Sydney, Sydney, Australia, November 2005.
- 111 “The Value of Stem Cells in Medical Research” St. Johns Episcopal Church, McLean, VA, December 2005.
- 112 “Inflammation’s Role in the Development and Progression of Prostate Cancer” NIH’s Lecture Series for Practicing Physicians, May 2006.
- 113 “The Importance of Pharmacogenetics in the Treatment of Cancer of the Prostate” 15th World Congress on Pharmacology, Beijing, China, July, 2006.
- 114 “Combination of Angiogenesis Inhibitor and Chemotherapy in the Treatment of AIPC” 6th Annual Congress on Prostate Cancer, Boca Raton, FL, July 2006.

- 115 “Genetic Evidence of Evolution” St. Johns Episcopal Church, McLean, VA, August 2006.
- 116 “Public Policy and Healthcare Outcomes” Columbia University School of Public Health, New York, NY, September 2006.
- 117 “Development of Thalidomide as an Angiogenesis Inhibitor – from Screening to the Clinic” The Angiogenesis Foundation’s 4th Annual International Conference, Boston, MA, October 2006.
- 118 “Development of Angiogenesis Inhibitors – from Screening to the Clinic” eCheminfo InterAction Meeting, Bryn Mawr College, Philadelphia, PA, October 2006.
- 119 “Pathway for the Development of PharmD Independent Researchers” National Institutes of Health Conference on Pharmacy Research, December 2006.
- 120 “Career Options in Pharmacy” National Institutes of Health IRTA post-bac Program, January 2007.
- 121 “Clinical Pharmacologist: Supply and Demand” University of Minnesota College of Pharmacy Graduate Student Program, May 2007.
- 122 “Opportunities for Science at the NIH” University of Maryland Graduate Student Retreat, Hapers Ferry, WV, June 2007.
- 123 “Molecular Pharmacology of CPS49” Dartmouth College, Department of Pharmacology and Toxicology Annual Graduate Student Seminar, Hanover, NH, June 2007.
- 124 “Identification and Validation of Biomarkers in Cancer” American College of Clinical Pharmacology, Denver, CO, October 2007.
- 125 “The Impact of the Human Genome Project on Drug Development” Tyson’s Corner Rotary Club, McLean, VA, November 2007.
- 126 “Pharmacogenetics: Ethnic Differences” American Associate of Cancer Research, Atlanta, GA, November 2007.
- 127 “Thalidomide in Solid Tumors” Chinese Clinical Pharmacologist NIH Meeting, Bethesda, MD, December 2007.
- 128 “Sorafenib in Prostate Cancer” Bayer Review of Sorafenib in Solid Tumors, Chicago, IL, April 2008.
- 129 “Review of the Last 5 Years of Nobel Prizes in Physiology and Medicine” St. John’s Episcopal Church, McLean, VA, April 2008.
- 130 “Candidate Gene vs High Through Genotyping” Affymetrix, San Francisco, CA, April 2008.
- 131 “Use Your Degree to Make a Difference” Samford University Commencement Address, Birmingham, AL, May 2008.

Research Funding and CRADA Support:

National Institutes of Health, National Cancer Institute, Clinical Pharmacology Program and Molecular Pharmacology Section, MOB - Intramural Funding - 7/92 - present - all projects

élan Pharmaceutical Company - \$450,000 CRADA (#0139) - 1995-1996 - Principal Investigator
“Clinical and Preclinical Development of Phenylbutyrate as an Anticancer Agent”

NIH Office of Minority Health - \$1,631,000 - 1997-2000 - Principal Investigator “Determining the Correlation Between Androgen Receptor CAG Trinucleotide Repeat Length and Prostate Cancer Risk”
Collaboration with Southwest Oncology Group

American College of Clinical Pharmacy Oncology Fellowship - \$20,000 - 1998- Principal Investigator
“Determination of CAG Repeat Length in the Exon 1 of the Androgen Receptor of Native American Men and Hispanic Men”

Unrestricted Gift from Frank J. McGuigan Trust - \$20,000 - 1997 - Principal Investigator
“Drug Development for Prostate Cancer”

Unrestricted Gift from Henry Benach Foundation - \$5,000 - Principal Investigator
"Drug Development for Prostate Cancer"

Celgene Pharmaceutical Company – CRADA (#01031) for development of CC5013 - \$460,000 - 2001 to 2008 - Principal Investigator

American Biosciences, Inc. – CRADA (#01892) for development of ABI-007 - \$49,000 - 2004 to 2007 - Principal Investigator

American College of Clinical Pharmacy Oncology Fellowship - \$25,000 - 2002 to 2004 - Principle Investigator

National Institutes of Health PO1 Grant “ Molecular Analysis of the PCPT” - Actual \$776,000 over 5 years, Total for P01 \$27,000,000 2005 to 2009 – Co-Principal Investigator on Project 1 and Co-Leader of Core B

Regeneron - CRADA 02054 “Effect of Vascular Endothelial Growth Factor (VEGF) Trap, a Protein Chimera Constructed from Two VEGF Receptors, on Tumor Growth and Metastasis in the Fetal Bone Metastasis Model” 06-05 to 06-07 - Principal Investigator

Novartis - M-CRADA 01297 “Research to Determine the Effect of Novartis Signal Transduction Inhibitor STI571 in LNCaP, a Prostate Cancer Cell Line 1-02 to 01-04 - Principal Investigator

Locus Pharmaceuticals - CRADA 01952 “Identification, Characterization and Development of Inhibitors that Act on Heat Shock Protein 90 (HSP90) using Locus Pharmaceutical, Inc.’s Core Technology” 12-04 to 12-08 - Principal Investigator

Guilford Pharmaceutical CRADA 00777 - 10-98 to 10-99 - Principal Investigator

Immunex M-CRADA 00620 - 09-97 to 09-98 - Principal Investigator

Center for Disease Control – 8/07 to present – Genetic Risk Factors for the Development of Cancer and Response to Cancer Treatment. \$750,000 – Principal Investigator

Research Funding and CRADA Support (cont.):

NCI Director's Innovation Award. \$50,000 – Principal Investigator

Patents and Licenses

Human Saphenous Vein Angiogenesis Assay - CuraGen Corp. – Licensed

Thalidomide Analogs for Inhibition of Angiogenesis

E-282-2000/0-US-01 Filed application provisional

E-282-2000/0-PCT-02 Filed application PCT

E-282-2000/0-US-07 Filed application Nat stage

PCT/US02/05868

2-(2,4-Difluoro-phenyl)-isoindole-1,3-dione
2-(2,4-Difluoro-phenyl)-4,7-dimethyl-isoindole-1,3-dione
2-(2,4-Difluoro-phenyl)-4,5,6,7-tetrafluoro-isoindole-1,3-dione
2-(2,4-Dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-4,5,6,7-tetrafluoro-isoindole-1,3-dione
2-(2,4-Dioxo-1-phenyl-1,2,3,4-tetrahydro-pyrimidin-5-yl)-isoindole-1,3-dione
2-(2,4-Dioxo-1-phenyl-1,2,3,4-tetrahydro-pyrimidin-5-yl)-4-nitro-isoindole-1,3-dione
2-(2,4-Dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-isoindole-1,3-dione
5-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-5-ethyl-1-phenyl-pyrimidine-2,4,6-trione
5-Ethyl-5-(4-nitro-1,3-dioxo-1,3-dihydro-isoindol-2-yl)-1-phenyl-pyrimidine-2,4,6-trione
1-Cyclohexyl-5-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-5-ethyl-pyrimidine-2,4,6-trione
5-Ethyl-1-phenyl-5-(4,5,6,7-tetrafluoro-1,3-dioxo-1,3-dihydro-isoindol-2-yl)-pyrimidine-2,4,6-trione
Licensed Dec. 2002 from the NIH to Celgene Corp.

Thalidomide and Thio-thalidomide Analogs for Inhibition of Angiogenesis and TNF- α

E-189-2003/0-EIR-00

E-189-2003/0- US-01

E-189-2003/0-PCT-02 Filed application PCT

E-189-2003/0-CN-08 Filed application Nat Stage

E-189-2003/0-US-03 Filed application US Pat application

PCT/US04/30506

2-(2,6-Dithioxo-piperidin-3-yl)-3-thioxo-2,3,3a,7a-tetrahydro-isoindol-1-one (Z-3-099 1)
2-(2-Oxo-6-thioxo-piperidin-3-yl)-3a,7a-dihydro-isoindole-1,3-dione (Z-2-085)
2-(1,3-Dithioxo-1,3,3a,7a-tetrahydro-isoindol-2-yl)-pentanedioic acid dimethyl ester (Z-3-013 1)
Acetic acid 6-(2,6-dioxo-piperidin-3-ylthiocarbonyl)-cyclohexa-2,4-dienyl ester (Z-3-103)
2-(2-Hydroxy-6-methoxy-pyridin-3-yl)-isoindole-1,3-dione hydrobromide (Z-2-087)
2-(2,6-Dihydroxy-pyridin-3-yl)-isoindole-1,3-dione hydrobromide (Z-2-093)
2-(2,6-Dioxo-1-phenethyl-piperidin-3-yl)-isoindole-1,3-dione (Z-2-105)
2-(2,6-Dioxo-piperidin-3-yl)-pyrrolo[3,4-c]pyridine-1,3-dione (Z-2-115)
3-(3-Oxo-2,3-dihydro-isoindol-1-ylidene)-piperidine-2,6-dione (Z-2-141)
2-(2,6-Dimethoxy-pyridin-3-yl)-isoindole-1,3-dithione (Z-2-165)
2-(2,6-Dioxo-piperidin-3-yl)-4-hydroxy-isoindole-1,3-dione (Z-3-171)
2-Benzyl-3-benzylimino-2,3-dihydro-isoindol-1-one (Z-3-055)
2-(1-Oxo-3-thioxo-1,3-dihydro-isoindol-2-yl)-pentanedioic acid (Z-3-063)
2-(2,6-Dithioxo-piperidin-3-yl)-isoindole-1,3-dione (Z-3-073 1)
2-(2-Oxo-6-thioxo-piperidin-3-yl)-3-thioxo-2,3-dihydro-isoindol-1-one (Z-3-073 II)
2-(2,6-Dioxo-piperidin-3-yl)-benzo[de]isoquinoline-1,3-dione (Z-3-091)
2-(2,6-Dioxo-piperidin-3-yl)-3a,9a-dihydro-benzo[f]isoindole-1,3-dione (Z-3-097)

(R) - 4,7,7-Trimethyl-3-oxo-2-oxa-bicyclo[2.2.1]heptane-1-carboxylic acid (2,6-dioxo-piperidin-3-yl)-amide (Z-3-106)
(S) - 4,7,7-Trimethyl-3-oxo-2-oxa-bicyclo[2.2.1]heptane-1-carboxylic acid (2,6-dioxo-piperidin-3-yl)-amide (Z-3-109)
Acetic acid 2-(2,6-dioxo-piperidin-3-ylcarbonyl)-phenyl ester (Z-3-149)
3-(2,6-Dimethoxy-pyridin-3-yl)-benzo[e][1,3]oxazine-2,4-dione (Z-3-147)
2-Cyclohex-2-enyl-isoindole-1,3-dithione (Z-2-157 I)
Isoindole-1,3-dithione (Z-2-122)
Pyrrolidine-2,5-dithione (Z-2-127)
2-(2,6-Dimethoxy-pyridin-3-yl)-isoindole-1,3-dione (Z-2-052)
2-(2-Oxo-6-thioxo-piperidin-3-yl)-isoindole-1,3-dione
3-(1-Oxo-3-thioxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
2-(2,6-Dithioxo-piperidin-3-yl)-isoindole-1,3-dione
2-(2-Oxo-6-thioxo-piperidin-3-yl)-3-thioxo-2,3-dihydro-isoindol-1-one
2-(2,6-Dithioxo-piperidin-3-yl)-3-thioxo-2,3-dihydro-isoindol-1-one
2-(1-Oxo-3-thioxo-1,3-dihydro-isoindol-2-yl)-pentanedioic acid dimethyl ester
2-(1,3-Dithioxo-1,3-dihydro-isoindol-2-yl)-pentanedioic acid dimethyl ester
2-(1-Oxo-3-thioxo-1,3-dihydro-isoindol-2-yl)-pentanedioic acid
6-Thioxo-piperidin-2-one
Piperidine-2,6-dithione
2-Cyclohex-2-enyl-isoindole-1,3-dithione
2-Cyclohex-2-enyl-3-thioxo-2,3-dihydro-isoindol-1-one
Isoindole-1,3-dithione
3-Thioxo-2,3-dihydro-isoindol-1-one

Cytochrome 1B1 Polymorphism Kit for Assessing Activity to Docetaxel

E-307-2005/0 EIR-00

E-307-2005/0-US-01 Filed application provisional

US Provisional Application No 60/716,439 filed 9/05

ABCBI Genotyping to Predict Microtubule-Stabilizing Agent Induced Toxicity

E-237-2006/0-EIR-00

E-237-2006/0-US-01 Filed application provisional

Tetrahalogenated Compounds useful as Inhibitors

US Provisional 60/798,098 Filed 13 April 06

E-080-2006

1-Cyclohexyl-5-ethyl-5-(4,5,6,7-tetrafluoro-1,3-dioxo-1,3-dihydro-isoindol-2-yl)-pyrimidine-2,4,6-trione (Gu977)
1-Ethyl-5-methyl-5-(4,5,6,7-tetrafluoro-1,3-dioxo-1,3-dihydro-isoindol-2-yl)-pyrimidine-2,4,6-trione (Gu973)
1-Cyclohexyl-5-methyl-5-(4,5,6,7-tetrafluoro-1,3-dioxo-1,3-dihydro-isoindol-2-yl)-pyrimidine-2,4,6-trione (Gu974)
5-Methyl-1-propyl-5-(4,5,6,7-tetrafluoro-1,3-dioxo-1,3-dihydro-isoindol-2-yl)-pyrimidine-2,4,6-trione (Gu997)
1,5-Diethyl-5-(4,5,6,7-tetrafluoro-1,3-dioxo-1,3-dihydro-isoindol-2-yl)-pyrimidine-2,4,6-trione (Gu987)
5-Ethyl-1-isopropyl-5-(4,5,6,7-tetrafluoro-1,3-dioxo-1,3-dihydro-isoindol-2-yl)-pyrimidine-2,4,6-trione
1-Isopropyl-5-methyl-5-(4,5,6,7-tetrafluoro-1,3-dioxo-1,3-dihydro-isoindol-2-yl)-pyrimidine-2,4,6-trione (Gu993)
1,5-Dimethyl-5-(4,5,6,7-tetrafluoro-1,3-dioxo-1,3-dihydro-isoindol-2-yl)-pyrimidine-2,4,6-trione (Gu1000)

5-Ethyl-1-propyl-5-(4,5,6,7-tetrafluoro-1,3-dioxo-1,3-dihydro-isoindol-2-yl)-pyrimidine-2,4,6-trione (Gu998)

N-(1-Ethyl-5-methyl-2,4,6-trioxo-hexahydro-pyrimidin-5-yl)-2,3,4,5-tetrafluoro-benzamide (Gu965)

N-(1-Cyclohexyl-5-methyl-2,4,6-trioxo-hexahydro-pyrimidin-5-yl)-2,3,4,5-tetrafluoro-benzamide (Gu976)

N-(1-Cyclohexyl-5-ethyl-2,4,6-trioxo-hexahydro-pyrimidin-5-yl)-2,3,4,5-tetrafluoro-benzamide (Gu978)

2,3,4,5-Tetrafluoro-N-(5-methyl-2,4,6-trioxo-1-propyl-hexahydro-pyrimidin-5-yl)-benzamide (Gu1030)

N-(1,5-Diethyl-2,4,6-trioxo-hexahydro-pyrimidin-5-yl)-2,3,4,5-tetrafluoro-benzamide (Gu1029)

N-(5-Ethyl-1-isopropyl-2,4,6-trioxo-hexahydro-pyrimidin-5-yl)-2,3,4,5-tetrafluoro-benzamide (Gu992)

N-(5-Ethyl-2,4,6-trioxo-1-propyl-hexahydro-pyrimidin-5-yl)-2,3,4,5-tetrafluoro-benzamide (Gu1031)

2,3,4,5-Tetrafluoro-N-(1-isopropyl-5-methyl-2,4,6-trioxo-hexahydro-pyrimidin-5-yl)-benzamide (Gu1032)

N-(1,5-Dimethyl-2,4,6-trioxo-hexahydro-pyrimidin-5-yl)-2,3,4,5-tetrafluoro-benzamide (Gu1016)

N-(5-Ethyl-2,4,6-trioxo-1-phenyl-hexahydro-pyrimidin-5-yl)-2,3,4,5-tetrafluoro-benzamide (Gu984)

Staff Scientist Working with Dr. Figg

Doug Price, Ph.D., 12/99 to present, Staff Scientist, Molecular Pharmacology Section, NCI
Alex Sparreboom, Ph.D., 11/02 to 7/06, Currently PI, St. Judes Childrens Research Hospital
Erin Gardner, Ph.D., 4/08 to present, SAIC Pharmacologist, Clinical Pharmacology Program

Post-Doctoral Fellows and Visiting Fellows Trained Under Dr. Figg

Richard Lush, Ph.D., 10/94 to 12/97, Currently, Executive Director Clinical Research, H. Lee Moffitt Cancer Center
Bradley Simmons, Ph.D., 9/95 to 4/97, Currently, Senior Analytical Chemist for US Pharmacopia
Shannon Dixon, Ph.D., 9/95 to 10/00, Currently, High School Science Teacher
Kenneth Bauer, Pharm.D., Ph.D., 5/98 to 5/99, Currently, Associate Professor and Head of Clinical Pharmacology Core, Univ. of Maryland Cancer Center
Helen H. Cho, Pharm.D., 4/97 to 8/98, Currently, Medical Manager, Roche Korea Co., Seoul, South Korea
Jozsef Horti, M.D., Ph.D., 8/96 to 9/98, Currently, Associate Professor, Ntl Inst of Oncology, Budapest, Hungary
Min Hee Kang, Pharm.D., M.S., 8/98 to 9/01, Currently, Assistant Professor, University of Southern California Keck School of Medicine
Suoping Zhai, M.D., Ph.D., 6/98 to 11/03, Currently, Clinical Pharmacologist, Roche Pharmaceutical
Huachun Chen, Ph.D., 8/98 to 12/98, Currently, Associate Director, Clinical Pharmacology, Eisai Medical
Sonia Kim, Pharm.D., MS, 7/99 to 9/01, Currently, Clinical Pharmacist, Fairfax Hospital
Waverly Woo, Pharm.D., Ph.D., 5/99 to 6/02, passed away 6/02
Yuichi Ando, M.D., Ph.D., 9/99 to 10/02, Currently, Associate Professor, Nagoya Medical School, Nagoya, Japan
Sitara Kommareddi, M.D., 7/99 to 5/00, Currently, Staff Surgeon, University of Arizona
Eiichi Fuse, Ph.D., 4/00 to 4/01, Currently, Senior Clinical Pharmacologist, Kyowa Pharmaceutical, Inc.
Gordon Macpherson, Ph.D., 11/01 to 4/04, Currently, Scientist, Human Genome Sciences, Inc.
Sylvia Ng, Ph.D., 11/01 to 5/04, Currently, Assistant Professor, University of British Columbia, Canada
Kyung Hwa Hwang, Ph.D., 3/02 to 7/06, Currently, Associate Professor, University of Southern California
Michael Cox, Pharm.D., 9/02 to 1/06, Currently, Associate Director, Amgen, Inc.
Nicola Smith, Ph.D., 10/03 to 4/06, Currently, Staff Pharmacologist, DTP, NCI
Luca Paoluzzi, M.D., 8/03 to 7/04, Currently, Instructor Columbia University, New York
Charity Scripture, Pharm.D., M.S., 4/04 to 1/06, Currently, Staff Scientist, NCI.
Cindy Chau, Pharm.D., Ph.D., 9/04 to present, Molecular Pharmacology Section, NCI
Haiqing Li, MD, Ph.D., 10/04 to 4/07, Currently, Staff Scientist in Technology Transfer Branch, NCI
Amy Sion, Pharm.D., 6/06 to 3/07, Currently, Hospital Investigational Pharmacists
Tania Alchalabi, M.D., 7/06 to 7/07, Currently, Resident in Family Practice, University of Michigan
Xiaohong Chen, Ph.D., 9/06 to present, Clinical Pharmacology Program, NCI
Haihao Sun, Ph.D., 7/07 to present, Clinical Pharmacology Program, NCI
Maria Silvina Frech, Ph.D., 9/07 to 1/08, Currently, Fellow at Georgetown University
Sukyung Woo, Ph.D., 1/08 to present, Clinical Pharmacology Program, NCI

Medical Oncology and Urology Fellows Trained Under Dr. Figg

Alain Thibault, M.D., 7/93 to 1/94, Currently, Medical Officer, Regeneron Biotech
Christopher Bowden, M.D., 1/94 to 7/94, Currently, Medical Officer, Genentech, Inc
Roberto Bitton, M.D., 10/94 to 6/95, Currently, Coordinator of Oncology Program, Elea Laboratorio
Yinong Liu, M.D., Ph.D., 1/02 to 7/03, Currently, Medical Oncologist in Private Practice, Danville, KY
Michael Franks, M.D., 1/03 to 7/04, Currently, Assistant Professor, University of Pittsburgh, Department of Urology
Avi Retter, M.D., 7/03 to 7/05, Currently, Medical Oncologist in Private Practice, New York, NY
Edwin Posadas, M.D., 7/03 to 7/05, Currently, Instructor, University of Chicago School of Medicine

William Douglas Figg

Curriculum Vitae

Page 51 of 57

Shenhong Wu, M.D., 7/05 to 7/06, Currently, Assistant Professor, SUNY at Stony Brook, NY
Chris Ahler, M.D., 7/05 to 7/07, Currently, Associate Director, Bristol Myers Squibb Pharmaceutical
Jeanny Aragon-Ching, M.D., 10/06 to 6/08, Currently, Assistant Professor, George Washington University
Nima Sharifi, M.D., 7/07 to 3/08, Currently, Assistant Professor, Texas Southwestern University

Visiting Professors working with Dr. Figg:

Juliann Chen, Pharm.D., 7/02 to 9/02, Visiting Professor from the University of Illinois
Romano Danesi, M.D., Ph.D., 8/03 to 9/03; 7/04 to 8/04; 7/05 to 8/05; 7/06 to 9/06; 7/07 to 9/07; 7/08 to 9/08; Visiting Professor from University of Pisca, Italy
Amanda Corbett, Pharm.D., 9/04 to 9/04, Visiting Professor from University of North Carolina
Casey Laizure, Pharm.D., 5/05 to 6/05, Visiting Professor from the University of Tennessee
Akinobu Hamada, Ph.D., 8/05 to 7/07, Visiting Professor from Kumamoto University, Japan
Valentina Rioja, Ph.D., 10/05 to 11/05, Visiting Scientist from the University of Milan, Italy
Lisa Davis, Pharm.D., 5/06 to 5/06, Visiting Professor from Philadelphia College of Pharmacy
Chiya Imamura, Ph.D., 11/07 to present, Visiting Professor from Keio University, Japan
Antonello Di Paolo, Ph.D., 1/08 to 2/08, Visiting Professor from University of Pisca, Italy

Research Associates working with Dr. Figg:

Jing Yu, MD 7/98 to 7/99
Razi Raziuddin, Ph.D., 4/99 to 2/00
Patricia Fernandez, Ph.D., 10/99 to 12/00
Misha Blagosklonny, MD, 7/99 to 7/01
Erin Gardner, M.S., 7/06 to 4/08
Weixin Wang, Ph.D., 10/07 to present

Graduate Students who completed their PhD Thesis under Dr. Figg:

Kenneth Bauer, Pharm.D. PhD., 5/96 to 5/99, Ph.D. Degree from the University of Pittsburgh;
Currently, Associate Professor, University of Maryland Cancer Center.
Thesis "The molecular and clinical pharmacology of carboxyamido-triazole, and a clinical trial in prostate cancer"

Michelle Rudek, Pharm.D., Ph.D. 7/96 to 7/01, Ph.D. Degree from the Virginia Commonwealth University; Currently, Assistant Professor and Head of Analytical Core, Johns Hopkins University Cancer Center.
Thesis "Evaluation of the pharmacokinetic-pharmacodynamic relationship for the matrix metalloproteinase inhibitory effect of COL-3 following oral administration to patients with refractory metastatic cancer"

Nehal Lakhani, MBBS, 8/00 to 7/05 Ph.D. Degree from Virginia Commonwealth University;
Currently, Medical Oncology Fellow, National Cancer Institute
Thesis "Evaluation of the Pharmacokinetic-Pharmacodynamic Relationship, Metabolism and Plasma Protein Binding of the Novel Antitumor Agent, 2 Methoxyestradiol (2ME2), Following Oral Administration in Patients with Solid Tumors"

Milin Acharya, M.S., 8/01 to 9/05, Ph.D. Degree Virginia Commonwealth University;
Currently, Pharmacologists at Johnson and Johnson Pharmaceutical.
Thesis "Clinical pharmacology of MS-275, a histone deacetylase inhibitor"

Tanyifor Tohnya, Pharm.D., 8/01 to 12/07, Ph.D. Candidate – did not complete, Virginia Commonwealth University; Currently, Clinical Pharmacologists at Genentech.

Tristan Sissung, M.S., 7/03 to 5/08, Ph.D. Candidate, George Washington University.
Thesis "Genetic factors that alter the pharmacodynamics of antineoplastic agents independent of alterations in pharmacokinetics"

Da Zhang, M.S., 7/05 to 10/07, Ph.D. Candidate – did not complete, Virginia Commonwealth University

Chun Nie, M.S., 7/06 to 5/07, Ph.D. Candidate – did not complete, Virginia Commonwealth University

Lokesh Jain, M.Pharm., 7/06 to present, Ph.D. Candidate, Virginia Commonwealth University

William Douglas Figg

Curriculum Vitae

Page 52 of 57

Kristinia Cook, B.S., 8/05 to present, Ph.D. Candidate, Oxford University
Rui Gao, M.S., 9/05 to present, Ph.D. Candidate, University of Maryland
Heather Pressler, B.S., 5/08 to present, Ph.D. Candidate, Johns Hopkins University

Residents, Students, Laboratory Assistants under Dr. Figg:

Natalie McCall, B.S., 7/92 to 2/97, Towson State University
Sophia Boudoulas, B.S., 8/94 to 8/95, Ohio State University
Sophia Boudoulas, B.S., 9/96 to 8/97, George Washington University School of Public Health
Bernadette Allman, B.S., 2/94 to 7/94, University of Maryland
Bruce Waldrop, B.S., 1/94 to 2/94, Samford University School of Pharmacy
Jennifer Stevens, B.S., 1/94 to 8/94, Cornell University
Kara Ammerman, B.S., 5/94 to 8/94, University of Pennsylvania
Nathan Ryan, 5/94 to 8/94, 5/95 to 8/95, 5/96 to 8/96 Bard College, Howard Hughes Summer Student
Matthew Middleman, 1/95 to 8/95, Cornell University
Barabara Soriano, B.S., 6/95 to 8/95, University of Pennsylvania
Mary Anna Denman, 8/95 to 12/95, Cornell University
Melissa Sutherland, 8/95 to 12/95, 5/96 to 8/96 Cornell University
Alexandra Zellas, B.S., 9/95 to 1/98, Hood College
Jordan Lisella, 1/96 to 5/96, Cornell University
Valerie Makarick, 1/96 to 5/96, Cornell University
Christina Giordano, 1/96 to 5/96, Cornell University
Rima Putta, 1/96 to 5/96, Cornell University
Jonathan Feuer, B.S., 7/96 to 8/97, Cornell University
Yi Guo, 6/96 to 8/96, University of Manchester/George Washington University
Yi Guo, B.S., 3/97 to 4/98, George Washington University
Kathryn Getek, 7/96 to 8/96, 6/97 to 7/97 Princeton University, Howard Hughes Fellow
Geeta Sagar, 9/96 to 12/96, Gallaudet University
Judith Smith, 10/96 to 12/96, Albany College of Pharmacy
Anne Negrin, 1/97 to 5/97, Cornell University
Sangeeta Raja, M.S., 3/97 to 8/97, University of North Dakota
Sangeeta Raja, M.S., 8/97 to 8/98, Ph.D. Candidate, University of Maryland
Ifey Arah, B.S., 5/97 to 5/98, University of Maryland
Carolyn Shih, 6/97 to 8/97, 6/98 to 7/98 Brown University
Victor Llorens, 6/97 to 9/97, Gaithersburg High School
Neil Hithcock, 11/97 to 12/97, Samford University School of Pharmacy
Belinda Kwong, 8/97 to 12/97, Cornell University
Lilian Wang, 6/97 to 8/97, Princeton University
Mike Leedom, B.S., 8/97 to 2/98, James Madison University
Nicole Pavick, B.S., 8/97 to 1/98, Boston College
Kristen Guest, 10/97 to 12/97, Penn State University
Julian Reed, 6/98 to 8/98, Xavier University
Margaret Johnson, 5/98 to 8/98, 6/00 to 8/00 University of Virginia
Kelly Cude, B.S., 8/98 to 8/99, University of California, Davis
John Lee, 7/98 to 8/98, University of California, Berkley
Manina Kaur, 5/98 to 8/98, University of Maryland
Manina Kaur, B.S., 6/99 to 8/99, University of Maryland School of Pharmacy
Erwin Kruger, B.A., 8/98 to 9/01, Harvard University
Josh Blumenfeld, 6/98 to 8/98, Charles E. Smith Jewish Day School
Shahrzad Movafagh, B.S., 8/98 to 4/99, University of Maryland
Nina Lee, 9/98 to 12/98, Cornell University
Kristen Stathis, 9/98 to 12/98, Cornell University
Samer Nuwayhid, B.S., 1/99 to 5/00, Samford University
Jeff Montgomery, B.S., 8/99 to 5/00, Columbia University College of Physicians and Surgeons
Cara Kurlander, 6/99 to 8/99, University of Chicago

William Douglas Figg

Curriculum Vitae

Page 53 of 57

Lisa Meister, 6/99 to 8/99, Columbia University
Brooke Haehl, B.S., 5/99 to 10/99, University of Virginia
Michael Cox, B.S., 11/99 to 12/99, Ohio Northern School of Pharmacy
Siiri Forbes, B.S., 1/00 to 8/02, University of Wisconsin
Amanda Reed, 6/00 to 8/00, Groves City High School
Catherine Morris, 10/99 to 6/002, Columbia University
Michael Weiss, B.S., 5/00 to 9/00, University of Leipzig, Germany
Patricia Ross, B.S., 8/00 to 9/00, Shenandoah University School of Pharmacy
Michelle Becker, B.S., 10/00 to 11/00, University of Kansas School of Pharmacy
Justin Brockbank, B.S., 12/00 to 8/01, Brigham Young University
Samantha Smith, 10/00 to 12/00, Wittenberg College
Kevin Haynes, B.S., 2/01 to 3/01, Ohio Northern School of Pharmacy
Andrew Trella, B.S., 5/01 to 8/01, University of North Carolina, Chapel Hill School of Pharmacy
Theresa Ferrara, B.S., 6/01 to 9/04 William and Mary College
Melinda Brown, B.S., 10/01 to 11/01, Samford University School of Pharmacy
Belinda Cheung, B.S., 11/01 to 12/01, University of Wisconsin School of Pharmacy
Anna Vitebsky, 9/01 to 12/01, Cornell University
Helene Bichel, B.S., 1/02 to 2/02, Shenandoah University School of Pharmacy
Andrada Tomoia-Cotisel, 6/02 to 8/02, Stanford University
Christopher Orr, 7/02 to 8/02, Landen High School
Bernard Lee, 6/02 to 8/02, Rutgers School of Pharmacy
Erin Lepper Gardner, M.S., 8/02 to 7/06, Oxford University, UK
James Wang, B.S. 11/02 to 12/02, Uniformed Health Services Medical School
Shubh Sharma, B.S., 11/02 to 7/03, American University
Lara Dunn, 1/03 to 8/03, Cornell University
Drew Goodman, 9/03 to 5/04, Winston Churchill High School
Elissa Brockbank, 6/03 to 8/03, 5/04 to 8/04 Brigham Young University
Anna Vitebsky, B.S., 6/03 to 7/03, Columbia University Graduate School
Kevin Hicks, 5/03 to 10/03, University of Michigan School of Pharmacy
Andrada Tomoia-Cotisel, 6/03 to 8/03, Stanford University
Roxane Fan, 6/03 to 11/03, St. John's Prep School
Daniell Ahn, B.S., 6/03 to 8/03, University of Virginia School of Medicine
Kathryn Peterson, 1/04 to 2/04, Samford University School of Pharmacy
Arun Singh, B.S., 8/03 to 9/04, Howard Hughes Medical Institute Scholar, NCI
And 3rd year medical student, New Jersey Medical School
Matthew Permenter, B.S., 2/03 to 1/06, Penn State University
Lorna Graham, B.S., 10/03 to 11/03, California State University
Arjun Achutuni, 9/03 to 5/04, Thomas Wootten High School
Sarah Prasse, 1/04 to 9/04, Cornell University
Brian Everist, 6/04 to 8/04, University of Kansas Medical School
Andrew Daniels, 6/04 to 5/05, University of Maryland
Ashley Tran, 10/04 to 11/04, Western University School of Pharmacy
Gareth Peters, B.S., 2/04 to present, George Mason University
Kathy Compton, B.S., 9/04 to present, James Madison University
Diana Roame, 1/04 to present, University of the District of Columbia
Michael Loggia, 8/04 to 1/05, Thomas Wootten High School
Katherine Cochrane, 10/04 to 8/05, Madeira High School
Caitlin Fennell, 10/04 to 6/05, Walter Johnson High School
Tracy Mak, 1/05 to 5/05, Cornell University
Andy Yost, 1/05 to 5/05, Cornell University
Laura Pang, 5/05 to 8/05, University of Pennsylvania
Vicky Tkacz, 5/05 to 8/05, Ohio State University
Calvin Kwon, 8/05 to 9/05, Langley High School
Sherrod Taylor, 7/05 to 8/05, University of Mississippi

William Douglas Figg

Curriculum Vitae

Page 54 of 57

Priyanka Goel, BS, 7/05 to 9/05, Carnegie Mellon University
Clint Hensley, BS, 8/05 to 9/05, San Diego State University
Erika Smith, BS, 1/06 to 8/08, Penn State University
Saurabh Agarwal, 1/04 to 6/04, Cornell University
Ritchie Longoria, 6/04 to 8/04, University of Tennessee School of Pharmacy
Jennifer Christenson, 11/04 to 12/04, University of Houston School of Pharmacy
Matt Danish, B.S., 9/06 to 8/08, University of Rochester
Sandra Ockers, B.S., 6/06 to 7/08, Davidson College
David Jiang, 9/06 to 12/06, Colgate University
Julie Barber, B.S., 7/06 to 9/06, Georgetown University Graduate Program
Jake Beverage, B.S., 6/06 to 8/06, University of California at San Francisco School of Pharmacy
Caitlin Baum, 5/06 to 2/07, University of Maryland
Michael Choi, 7/06 to 5/07, Thomas Jefferson High School
Ellie Shuo Hong, 6/06 to 8/06, Phillips Exeter Academy
Heather Tomaszewski, 5/06 to 8/06, Virginia Tech University
Rui Gao, B.S., 7/06 to 9/06, University of Maryland Graduate Program
Poliana Andrade, 9/06 to 12/06, University of California at Davis
Martha Couch, 10/06 to 2/07, Broadneck High School
Diana Ziscovici, 9/06 to 5/07, Walter Johnson High School
Rebecca Nakles, B.S., 12/06 to 5/07, Georgetown University Graduate Program
Samantha Pula, 5/07 to 8/07, North Dakota State University School of Pharmacy
Shelby Davis, 5/07 to 8/07, Bowdin College
Jennifer Miles, 5/07 to 8/07, NOVA South East School of Pharmacy
Katy Thompson, 5/07 to 8/07, Georgetown College
Arnie Lehto, 5/07 to 8/07, Finland High School
Caitlin Baum, 6/07 to present, University of Maryland
Stephen Pisle, 9/07 to present, University of Maryland
Hanem Ali, 1/08 to present, Georgetown University
Randy Ochs, 6/08 to 8/08, Churchill High School
Heather Pressler, 11/07 to 4/08, Johns Hopkins University
Melissa Gilden, 6/08 to 8/08, University of Maryland
Jorge Luna, 6/08 to 8/08, Columbia University
Maggie Wolfe, 6/08 to 8/08, Columbia University
Daniel Yagoda, 6/08 to 8/08, Columbia University
Bevin English, B.S., 6/08 to present, Davidson College
Seun Ajiboye, B.S., 7/08 to present, Duke University
Craig Vargo, 6/08 to 8/08, Purdue University
Shandiz Shahbazi, 6/08 to 8/08, Oakton High School
Sarah Prasse, M.S., 6/08 to present, Georgetown University
Joey Miles, B.S., 6/08 to 8/08, Georgetown College

Ad Hoc Tenure/Promotion Reviews:

University of Kentucky
University of Tennessee
West Virginia University
University of Southern California
University of Connecticut
Purdue University
Duke University
Johns Hopkins University
University of Illinois at Chicago
University of California at San Diego
University of Maryland
University of Georgia
University of Minnesota

Grant or Program Review Committees:

Adult AIDS Clinical Trials Group, Pharmacology Grant Review Committee (1995)
Department of Defense's, Grant Review Committee on Breast Cancer (1996)
United Kingdom's Cancer Research Campaign, Grant Reviewer (1999-2008)
Italian Association for Cancer Research, Grant Reviewer (2002-2003)
Department of Defense, Ovarian Cancer Grant Review Committee (2002)
North Carolina Biotechnology Awards, Grant Reviewer (2003)
Maryland Biotechnology Awards, Grant Reviewer (2003)
Austrian Foundation for Scientific Development, Grant Reviewer (2004)
Avon-NCI Breast Cancer Progress Grant, Project Reviewer (2004)
Japan Society for Promotion of Science Fellowship Grant, Reviewer (2004)
Department of Defense, Prostate Cancer Integration Grant Committee (2004)
Grant Reviewer (2006)
American College of Clinical Pharmacy's Research Institute, Grant Priority Committee (2004-2005)
Johns Hopkins University's Master in Biotechnology Graduate Selection Committee (2004)
Japan Society for the Promotion of Science – Fellowship Selection Committee (2004)
National Institutes of Health Study Section (End Organ Disease) Grant Reviewer (2004)
Ministry of Health and Biomedical Research Council, Grant Reviewer, Singapore (2005, 2008)
NCI's Preclinical Pharmacology Extramural Grants Reviewer (2004)
Austrian Science Fund, Grant Reviewer (2005)
Cancer Research UK, Grant Reviewer (2005)
ACCP Research Institute
Chair of the Pharmacotherapy Grant Review Committee (2005)
Chair of the Hematology Oncology Grant Review Committee (2005)
Chair of the Investigator Development Award Review Committee (2005)
Reviewer – Career Development Award (2005 - 2006)
Reviewer - Fellowships in Oncology (1994 - 2001)
Reviewer - Grants in Oncology (1995 - present)
Chair, Grants and Fellowship Selection Committee (2006)
National Eye Institute, NIH, Board of Scientific Council, Intramural Site Visit Committee
For the Laboratory of Retinal Cell and Molecular Biology (2005)
West Virginia University Intramural Grant, Grant Reviewer (2006)
United Kingdom's Breast Cancer Campaign, Grant Reviewer (2006)
Austria Competence Center for Excellent Technologies, Grant Reviewed (2007)
The Wellcome Trust, Grant Reviewer (2007)
Rain Medical Research Foundation (The University of Western Australia), Grant Reviewer (2007)

Grant or Program Review Committees (cont.):

Christian Doppler Research Association, Austria, Grant Reviewer (2007)
National Medical Research Council, Singapore, Grant Reviewer (2007)
Isreal Science Foundation, Tel Viva, Grant Reviewer (2008)

Clinical Trials in Which Dr. Figg is Principal Investigator or Protocol Chair:

95-C-0178 A Randomized Phase II Study of Oral Thalidomide in Patients with Hormone Refractory Prostate Cancer

95-C-0161 – A Protocol to obtain Blood, Urine, and other Tissue samples for Research Purposes to Investigate Micrometastases and the Presence of PSA in the Urine

00-C-0080 - A Double Blind Randomized Crossover Phase III Study of Oral Thalidomide versus Placebo in Patients with Stage D0 Androgen Dependent Prostate Cancer Following Limited Hormonal Ablation

01-C-0256 - A Phase I Trial of 2-Methoxyestradiol (2ME2), an Angiogenesis Inhibitor, in Patients with Solid Tumors

02-C0083 - A Multidose Phase I Study of Oral CC5013, a Thalidomide Derivative, in Patients with Refractory Metastatic Cancer

02-C-0149 - A Phase I Trial of High Dose Ketoconazole plus Weekly Docetaxel in Metastatic Androgen Independent Prostate Cancer

02-C-0138 - Retrospective analysis of CYP2C19 genotype in Cancer Patients enrolled on Clinical Trials with Thalidomide at National Cancer Institute to Assess the in vivo Metabolisms, Pharmacokinetics and Pharmacodynamics of Thalidomide

02-C-0161 – Retrospective Analysis of Promoter Polymorphism of UGT1A1 Gene in Cancer Patients Enrolled on Clinical Trials with Flavopiridol at the National Cancer Institute to Assess the Pharmacokinetics and Pharmacodynamics of Flavopiridol

03-C-0153 - Retrospective analysis of endostatin genotype in prostate cancer patients to assess the association of a single nucleotide polymorphism (D104N) in endostatin and prostate cancer

03-C-0242 - Pharmacological Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute

04-C-N279 - Retrospective Analysis of Drug Metabolizing Genotype in Cancer Patients and Correlation with Pharmacokinetic Data

04-C-0132 - A Phase II Trial Combining Estramustine, Docetaxel, and Thalidomide in Patients with Androgen-Independent Metastatic Prostate Cancer

04-C0257 - A Phase II Trial of Docetaxel, Thalidomide, Prednisone, and Bevacizumab in Patients with Androgen-Independent Prostate Cancer

04-C0280 - Randomized, Crossover, Pharmacokinetic study of Paclitaxel and ABI-007 in Patients with Advanced Solid Tumors

05-C-N090 - Analysis of ABCG2 genotype in Gleevec treated Cancer Patients to assess the Association of a Single Nucleotide Polymorphism (C421A) in ABCG2 and Response to Treatment

07-C-0059 - A Phase II Study of AZD2171 in metastatic Androgen Independent Prostate Cancer

07-C-0100 - Collection of Blood from Patients with Prostate Cancer